135 results on '"Korva M"'
Search Results
2. Hantavirus infections
- Author
-
Avšič-Županc, T., Saksida, A., and Korva, M.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
3. COVID-19 disease: monitoring of antibodies against SARS-CoV-2 virus in serum of a vitamin D sufficient male.
- Author
-
Osredkar, J., Rus, K. Resman, Korva, M., Kotar, T., Fabjan, K. T., Jerin, A., Siuka, D., and Avšič Županc, T.
- Subjects
COVID-19 ,SARS-CoV-2 ,VITAMIN D - Abstract
Background: COVID-19 presents with a range of symptoms from mild to severe, and some individuals remain asymptomatic. The appearance and decline of antibodies to SARS-CoV-2 varies with disease severity, age, and underlying health conditions. The time course of antibody decline also differs among individuals. Variants of the virus can evade neutralizing antibodies, which can affect vaccine efficacy. SARS-CoV-2 affects biochemical processes, resulting in an overactive immune response, increased risk of blood clots, impaired glucose metabolism, decreased insulin sensitivity, oxidative stress, and neurologic effects. Case presentation: This study followed antibody levels after SARS-CoV-2 infection and assessed the effects of vaccination on antibody levels over time. A 65-year-old COVID-19 patient was examined and diagnosed by a positive PCR test. The patient was not taking regular medications other than self-administered cholecalciferol. Regular follow-up, including telemetric monitoring and symptom assessment, was performed for one year. Conclusions: The results showed that antibody levels to SARS-CoV-2 spike protein and neutralizing antibodies were highest after vaccination and booster doses and gradually decreased over time. Of the biochemical parameters studied, only d-dimer and ferritin transiently exceeded reference values. Vitamin D consumption before infection may have had a positive influence on a milder course of the disease, as observed in other viral infections. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
4. Genetic diversity and macrolide resistance of Mycoplasma pneumoniae isolates from two consecutive epidemics in Slovenia
- Author
-
Kogoj, R., Praprotnik, M., Mrvič, T., Korva, M., and Keše, D.
- Published
- 2017
- Full Text
- View/download PDF
5. Viral load and immune response dynamics in patients with haemorrhagic fever with renal syndrome
- Author
-
Korva, M., Saksida, A., Kejzar, N., Schmaljohn, C., and Avŝiĉ-Zupanc, T.
- Published
- 2013
- Full Text
- View/download PDF
6. Supplement to: Zika virus associated with microcephaly.
- Author
-
Mlakar, J, Korva, M, and Tul, N
- Published
- 2016
7. Zika virus associated microcephaly/micrencephaly—fetal brain imaging in comparison with neuropathology
- Author
-
Vesnaver, T Vipotnik, Tul, N, Mehrabi, S, Parissone, F, Štrafela, P, Mlakar, J, Pižem, J, Korva, M, Zupanc, T Avšič, and Popović, M
- Published
- 2017
- Full Text
- View/download PDF
8. POS0072 COMPREHENSIVE IMMUNE PROFILING OF 20 CHILDREN WITH MULTISYSTEM INFLAMMATORY SYNDROME
- Author
-
Zajc Avramovic, M., primary, Emersic, N., additional, Kopitar, A. N., additional, Korva, M., additional, Avsic-Zupanc, T., additional, Ihan, A., additional, and Avcin, T., additional
- Published
- 2021
- Full Text
- View/download PDF
9. Distinct haplotype structure at the innate immune receptor Toll-like receptor 2 (TLR2) across bank vole populations and lineages in Europe
- Author
-
Morger, Jennifer, Raberg, L, Hille, S M, Helsen, S, Štefka, J, Al-Sabi, M M, Kapel, C M O, Mappes, T, Essbauer, S, Ulrich, R G, Bartolommei, P, Mortelliti, A, Balčiauskas, L, van den Brink, N W, Rémy, A, Bajer, A, Cheprakov, M, Korva, M, García-Pérez, A L, Biek, R, Withenshaw, S, Tschirren, Barbara, University of Zurich, and Tschirren, Barbara more...
- Subjects
balancing selection ,phylogeography ,diversity ,parasite resistance ,immunogenetics ,10127 Institute of Evolutionary Biology and Environmental Studies ,1105 Ecology, Evolution, Behavior and Systematics ,rodents ,Myodes glareolus ,gene evolution ,maintenance of genetic variation ,570 Life sciences ,biology ,590 Animals (Zoology) ,TLR2 - Published
- 2015
- Full Text
- View/download PDF
10. Zika virus associated microcephaly/micrencephaly—fetal brain imaging in comparison with neuropathology
- Author
-
Vesnaver, T Vipotnik, primary, Tul, N, additional, Mehrabi, S, additional, Parissone, F, additional, Štrafela, P, additional, Mlakar, J, additional, Pižem, J, additional, Korva, M, additional, Zupanc, T Avšič, additional, and Popović, M, additional more...
- Published
- 2016
- Full Text
- View/download PDF
11. Laboratory capability and surveillance testing for middle east respiratory syndrome coronavirus infection in the who European region, June 2013
- Author
-
Pereyaslov, D., Rosin, P., Palm, D., Zeller, H., Gross, D., Brown, C. S., Struelens, M. J., Robo, A., Hatibi, I. H., Alis, J. C., Sargsyan, S., Gurbanov, S., Gribkova, N., Ranst, M., Ieven, G., Patteet, S., Tomic, S., Korsun, N., Drazenovic, V., Pieridou-Bagkatzouni, D., Jirincova, H., Havlickova, M., Fomsgaard, A., Rae, K., Lappalainen, M., Ikonen, N., Lina, B., Sylvie van der WERF, Manuguerra, J. -C, Machablishvili, A., Eickmann, M., Wolff, T., Dobler, G., Schmidt-Chanasit, J., Drosten, C., Papa, A., Mentis, A. F., Kis, Z., Löve, A., Coughlan, S., Mandelboim, M., Capobianchi, M. R., Landini, M. P., Baldanti, F., Palu, G., Ghisetti, V., Donatelli, I., Nusupbayeva, G., Tokhtabakiyeva, Z., Kasymbekova, K., Storozenko, J., Erne, S., Griskevicius, A., Opp, M., Barbara, C., Vratnica, Z., Reusken, C., Dudman, S. G., Hungnes, O., Pancer, K., Guiomar, R., Eder, V., Lupulescu, E., Yatsyshina, S., Pisareva, M., Buzitskaya, Z., Sergeev, A., Nedeljković, J., Staroňová, E., Županc, T. A., Petrovec, M., Korva, M., Prosenc, K., Casas, I., Gaines, H., Cherpillod, P., Zakirova, N., Bosevska, G., Altas, B., Ciblak, M., Mironenko, A., Dykhanovska, T., Demchyshyna, I., Bermingham, A., Rakhimov, R., Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), Experts of the MERS-CoV Working Group Members of this working group who provided survey data: Albania: Alma Robo, Iris Hasibra (Hatibi), Institute of Public Health, Tirana Andorra: Josep Casals Alis, Ministry of Health, Welfare and Labour, Andorra la Vella Armenia: Shushan Sargsyan, Virology Laboratory, Centre for Diseases Control and Prevention, Yerevan Austria: Stephan Aberle, Department of Virology, Medical University of Vienna, Vienna Azerbaijan: Sadraddin Gurbanov, National Virology Laboratory, National Anti-Plague Station, Baku Belarus: Natalia Gribkova, Laboratory for Influenza and Influenza-like Diseases, Republican Research and Practical Center for Epidemiology and Microbiology, Minsk Belgium: Marc Van Ranst, Greet Ieven and Sophie Patteet, National Reference Centre of Respiratory Viruses, University Hospital Leuven and UZA Antwerpen, Antwerpen Bosnia and Herzegovina: Stanka Tomic, Microbiology Department, Institute of Public Health of the Republic of Srpska, Banja Luka Bulgaria: Neli Korsun, National Laboratory 'Influenza and ARD', Department of Virology, National Centre of Infectious and Parasitic Diseases, Sofia Croatia: Vladimir Drazenovic, National Influenza Centre, Croatian National Institute of Public Health, Zagreb Cyprus: Despo Pieridou-Bagkatzouni, Microbiology Department, Nicosia General Hospital, Nicosia Czech Republic: Helena Jirincova, Martina Havlickova, National Reference Laboratory for Influenza, National Institute for Public Health, Prague Denmark: Anders Fomsgaard, Virus Research and Development Laboratory, Department Microbiology Diagnostic and Virology, Statens Serum Institut, Copenhagen Estonia: Külli Rae, Laboratory of Communicable Diseases, Health Board, Tallinn Finland: Maija Lappalainen, Department of Virology and Immunology, Helsinki University Hospital, Laboratory Services (HUSLAB) and Niina Ikonen, Virology Unit, National Institute for Health and Welfare, Helsinki France: Bruno Lina, Centre National de Référence des Virus Influenza – HCL, Lyon and Sylvie van der Werf, Unit of Molecular Genetics of RNA viruses, Institut Pasteur and Jean-Claude Manuguerra, Cellule d’Intervention Biologique d’Urgence (CIBU), Institut Pasteur, Paris Georgia: Ann Machablishvili, National Influenza Centre, National Centre for Disease Control and Public Health, Tbilisi Germany: Markus Eickmann, Institut für Virologie der Philipps-Universität in Marburg and Thorsten Wolff, Div of Influenza and other Respiratory viruses, Robert Koch-Institut, and Dr. Gerhard Dobler, Bundeswehr Instittue of Microbiology, and Jonas Schmidt-Chanasit, WHOCC for Arbovirus and Haemorrhagic Fever Reference and Research at Bernhard Nocht Institute for Tropical Medicine, Hamburg, and Christian Drosten, Virology Institute, Bonn Greece: Anna Papa, National Reference Laboratory for Arboviruses and Hemorrhagic Fever viruses, Aristotle University of Thessaloniki, Thessaloniki and Andreas F. Mentis, National Influenza Reference Laboratory of Southern Greece/Hellenic Pasteur Institute, Athens Hungary: Zoltan Kis, Department for Respiratory Viruses / National Biosafety Laboratory, B. Johan National Center for Epidemiology, Budapest Iceland: Arthur Löve, Department of Virology, Landspitali- National University Hospital, Reykjavik Ireland: Suzie Coughlan, National Virus Reference Laboratory/University College Dublin, Dublin Israel: Michal Mandelboim, Central Virology Laboratory, Sheba Medical Center, Tel Hashomer Italy: Maria R. Capobianchi, Laboratory of Virology/National Institute for Infectious Diseases Lazzaro Spallanzani, and Maria Paola Landini, Regional Center for Emerging Infections (CRREM)/ Unit of Clinical Microbiology, St. Orsola General Hospital, Bologna, and Fausto Baldanti, Molecular Virology Unit, Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, and Giorgio Palu, Microbiology and Virology/Padova University Hospital, and Valeria Ghisetti, Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Torino, and Isabella Donatelli, National Influenza Centre, Instituto Superiore di Sanita, Kazakhstan: Gaukhar Nusupbayeva, Zarina Tokhtabakiyeva, National Reference Laboratory on Control of Viral Infections, Scientifical-Practical Center of Sanitary and Epidemiological Expertise and Monitoring, Almaty Kyrgyzstan: Kaliya Kasymbekova, Centre of Molecular-Genetic and Microbiological Investigations, Department of State Sanitary Epidemiological Surveillance, Bishkek Latvia: Jelena Storozenko, Riga East University Hospital, Latvian Centre of Infectious Diseases, National Microbiology Reference Laboratory, Riga Liechtenstein: Sabine Erne, Office of Public Health, Country Administration of Principality of Liechtenstein Lithuania: Algirdas Griskevicius, National Public Health Surveillance Laboratory, Vilnius Luxembourg: Matthias Opp, Laboratoire National de Santé, Luxembourg Malta: Christopher Barbara, Pathology Department, Mater Dei Hospital, Msida Montenegro: Zoran Vratnica, Centre for Medical Microbiology, Public Health Institute of Montenegro, Podgorica Netherlands: Chantal Reusken, Centre for Infectious Disease Research, Diagnostics and Screening, National Institute for Public Health and the Environment, Bilthoven Norway: Susanne Gjeruldsen Dudman and Olav Hungnes, Department of Virology, Norwegian Institute of Public Health, Oslo Poland: Katarzyna Pancer, National Institute of Public Health- National Institute of Hygiene, Department of Virology, Warsaw Portugal: Raquel Guiomar, National Influenza Reference Laboratory, Infectious Diseases Department, National Institute of Health, Lisboa Republic of Moldova: Veronica Eder, Laboratory of Viral Respiratory Infections, National Center for Public Health, Chisinau Romania: Emilia Lupulescu, Laboratory for Respiratory Viruses/ NIRDMI Cantacuzino, Bucharest Russian Federation: Svetlana Yatsyshina, Reference Centre for Infection Agents, Central Research Institute of Epidemiology (CRIE), Rospotrebnadzor, Moscow, and Maria Pisareva and Zhanna Buzitskaya, Laboratory of Molecular Virology and Genetic Engineering, Research Institute of Influenza, St Petersburg, and Alexander Sergeev, State Research Center of Virology and Biotechnology VECTOR, Novosibirsk Serbia: Jasminka Nedeljković, Respiratory Department, Torlak Institute of Immunology and Virology, Belgrade Slovakia: Edita Staroňová, National Influenza Center/Public Health Authority, Bratislava Slovenia: Tatjana Avšič Županc, Miroslav Petrovec, Miša Korva, University of Ljubljana, Faculty of Medicine, Institute of Microbiology and Immunology, and Katarina Prosenc, Laboratory for Virology, National Public Health Institute Slovenia, Ljubljana Spain: Inmaculada Casas, Influenza National Reference Laboratory, National Influenza Center-Madrid, Instituto de Salud Carlos III, Majadahonda, Madrid and Ramon Cisterna Clinical microbiology and infection control, Hospital Basurto Bilbao Spain Sweden: Hans Gaines, Swedish Institute for Communicable Disease Control, Stockholm Switzerland: Pascal Cherpillod, National Reference Centre for Emerging Viral Infections, Laboratory of Virology, Division of Infectious Diseases University of Geneva Hospitals, Geneva Tajikistan: Niginamo Zakirova, Virology Laboratory, State Sanitary-Epidemiological Surveillance, Dushanbe The former Yugoslav Republic of Macedonia: Golubinka Bosevska, Laboratory for Virology and Molecular Diagnostics, Institute of Public Health, Skopje Turkey: Basak Altas, National Influenza Centre, Virology Reference and Research Laboratory, Public Health Institutions of Turkey, Ankara, and Meral Ciblak, National Influenza Reference Laboratory, Faculty of Medicine, University of Istanbul, Istanbul Turkmenistan: Central Reference Laboratory, Sanitary Epidemiologic Service, Ashgabat Ukraine: Alla Mironenko, National Influenza Centre, L.V.Gromashevsky Institute of Epidemiology & Infectious diseases NAMS, and Tetiana Dykhanovska and Iryna Demchyshyna, Centre of influenza and ARVI, Central Sanitary and Epidemiological Station, Kiev United Kingdom: Alison Bermingham, Respiratory Virus Unit, Virus Reference Department, Public Health England, London Uzbekistan: Ravshan Rakhimov, National Influenza Centre, Institute of Virology, Tashkent., and We thank the ECDC National Microbiology Focal Points in EU/EEA countries, focal points from laboratories of the EuroFlu and ENIVD networks for coordinating data collection and for dedicated and rapid responses to the surveys. more...
- Subjects
Epidemiology ,Middle East respiratory syndrome coronavirus ,[SDV]Life Sciences [q-bio] ,SARS (Disease) ,MERS (Disease) ,medicine.disease_cause ,World Health Organization ,Communicable Diseases, Emerging ,World health ,Viral genetics ,Coronavirus infections -- Laboratory manuals ,Environmental protection ,Virology ,Environmental health ,medicine ,media_common.cataloged_instance ,Humans ,European Union ,European union ,Coronavirus ,media_common ,Middle East ,business.industry ,Reverse Transcriptase Polymerase Chain Reaction ,Public Health, Environmental and Occupational Health ,Reference Standards ,European region ,Health Surveys ,Diseases -- Causes and theories of causation ,Middle East Respiratory Syndrome Coronavirus ,RNA, Viral ,Disease prevention ,business ,Coronavirus Infections ,Laboratories ,Sentinel Surveillance ,Sequence Analysis - Abstract
Since September 2012, over 90 cases of respiratory disease caused by a novel coronavirus, now named Middle East respiratory syndrome coronavirus (MERS-CoV), have been reported in the Middle East and Europe. To ascertain the capabilities and testing experience of national reference laboratories across the World Health Organization (WHO) European Region to detect this virus, the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe conducted a joint survey in November 2012 and a follow-up survey in June 2013. In 2013, 29 of 52 responding WHO European Region countries and 24 of 31 countries of the European Union/European Economic Area (EU/EEA) had laboratory capabilities to detect and confirm MERS-CoV cases, compared with 22 of 46 and 18 of 30 countries, respectively, in 2012. By June 2013, more than 2,300 patients had been tested in 23 countries in the WHO European Region with nine laboratory-confirmed MERS-CoV cases. These data indicate that the Region has developed significant capability to detect this emerging virus in accordance with WHO and ECDC guidance. However, not all countries had developed capabilities, and the needs to do so should be addressed. This includes enhancing collaborations between countries to ensure diagnostic capabilities for surveillance of MERS-CoV infections across the European Region., peer-reviewed more...
- Published
- 2014
- Full Text
- View/download PDF
12. Genetic diversity and macrolide resistance of Mycoplasma pneumoniae isolates from two consecutive epidemics in Slovenia.
- Author
-
Kogoj, R., Praprotnik, M., Mrvič, T., Korva, M., and Keše, D.
- Subjects
MYCOPLASMA pneumoniae ,DRUG resistance in bacteria ,MACROLIDE antibiotics ,EPIDEMICS ,BACTERIAL genetics - Abstract
Two nationwide Mycoplasma pneumoniae epidemics occurred in Slovenia between 2006 and 2016. The aim of this study was to assess which M. pneumoniae genotypes were present in our area during the selected timeframe, whether the origin of the epidemics was monoclonal or polyclonal and whether the proportion between detected genotypes changed over time. We were also interested in the presence of macrolide resistance (MR) and whether it could be linked to specific genotypes. We performed pyrosequencing of the P1 gene and multiple-locus variable-number tandem repeat (VNTR) analysis (MLVA) typing from 872 M. pneumoniae isolates obtained from respiratory tract infections (RTI)-suffering patients. Additionally, isolates were tested for the presence of MR implicated mutations in the 23S rRNA gene. The MLVA typing results revealed that three main genotypes, MLVA-3,5,6,2, MLVA-3,6,6,2 and MLVA-4,5,7,2, were constantly present and occasionally joined by less abundant, short-lived genotypes, which were detected mostly, but not exclusively, during epidemics. We also noticed a switch in abundance from MLVA-3,5,6,2 and MLVA-3,6,6,2, which dominated in the first epidemic (77.0%; 97/126), to MLVA-4,5,7,2 (71.6%; 428/598), which dominated in the second. Similar to this finding, the dominant P1 type also shifted from type 2 to type 1, although a complete P1 type shift was not observed, since both types remained in circulation. MR was detected in 0.8% (7/872) of M. pneumoniae isolates. Our results seem to suggest that MR remains sporadic in Slovenia at this point in time and that both recent epidemics were polyclonal in nature and, possibly, to some extent, fuelled by the P1 type dominance change. [ABSTRACT FROM AUTHOR] more...
- Published
- 2018
- Full Text
- View/download PDF
13. First multicentre evaluation of serological and molecular diagnostic assays for Crimean-Congo hemorrhagic fever
- Author
-
Vanhomwegen, J., primary, Alves, M.J., additional, Avsic-Zupanc, T., additional, Bino, S., additional, Chinikar, S., additional, Karlberg, H., additional, Korukluoğlu, G., additional, Korva, M., additional, Mardani, M., additional, Mirazimi, A., additional, Mousavi, M., additional, Papa, A., additional, Saksida, A., additional, Sharifi-Mood, B., additional, Sidira, P., additional, Tsergouli, K., additional, Woelfel, R., additional, Zeller, H., additional, and Dubois, P., additional more...
- Published
- 2012
- Full Text
- View/download PDF
14. Increased number of cases of haemorrhagic fever with renal syndrome in Slovenia, January to April 2012
- Author
-
Kraigher, A, primary, Frelih, T, additional, Korva, M, additional, and Avsic, T, additional
- Published
- 2012
- Full Text
- View/download PDF
15. Dobrava virus RNA load in patients who have hemorrhagic fever with renal syndrome.
- Author
-
Saksida A, Duh D, Korva M, and Avsic-Zupanc T
- Abstract
To asses the role of virus load in the pathogenesis of hemorrhagic fever with renal syndrome, the serum Dobrava virus RNA load in 46 patients was measured with a novel quantitative real-time reverse-transcriptase polymerase chain reaction assay and compared to the disease severity. The level of viremia, detected in 26 patients, ranged from 10(2)-10(8) copies/mL of serum. The patients with severe disease had, on average, higher viral RNA loads than patients with a milder course of disease (6.15 vs. 4.67 log(10) copies/mL; P = .053). These results suggest that the Dobrava virus load might be associated with the severity of disease. Copyright © 2008 Infectious Diseases Society of America [ABSTRACT FROM AUTHOR] more...
- Published
- 2008
- Full Text
- View/download PDF
16. Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020
- Author
-
Alm E., Broberg E.K., Connor T., Hodcroft E.B., Komissarov A.B., Maurer-Stroh S., Melidou A., Neher R.A., O'Toole A., Pereyaslov D., Beerenwinkel N., Posada-Cespedes S., Jablonski K.P., Ferreira P.F., Topolsky I., Avsic-Zupanc T., Korva M., Poljak M., Zakotnik S., Zorec T.M., Bragstad K., Hungnes O., Stene-Johansen K., Reusken C., Meijer A., Vennema H., Ruiz-Roldan L., Bracho M.A., Garcia-Gonzalez N., Chiner-Oms A., Cancino-Munoz I., Comas I., Goig G.A., Torres-Puente M., Lopez M.G., Martinez-Priego L., D'Auria G., Ruiz-Hueso P., Ferrus-Abad L., de Marco G., Galan-Vendrell I., Carbo-Ramirez S., Ruiz-Rodriguez P., Coscolla M., Polackova K., Kramna L., Cinek O., Richter J., Krashias G., Tryfonos C., Bashiardes S., Koptides D., Christodoulou C., Bartolini B., Gruber C.E., Di Caro A., Castilletti C., Stefani F., Rimoldi S.G., Romeri F., Salerno F., Polesello S., Nagy A., Jirincova H., Vecerova J., Novakova L., Cordey S., Murtskhvaladze M., Kotaria N., Schar T., Beisel C., Vugrek O., Rokic F., Trgovec-Greif L., Jurak I., Rukavina T., Sucic N., Schonning K., Karst S.M., Kirkegaard R.H., Michaelsen T.Y., Sorensen E.A., Knutson S., Brandt J., Le-Quy V., Sorensen T., Petersen C., Pedersen M.S., Larsen S.L., Skov M.N., Rasmussen M., Fonager J., Fomsgaard A., Maksyutov R.A., Gavrilova E.V., Pyankov O.V., Bodnev S.A., Tregubchak T.V., Shvalov A.N., Antonets D.V., Resende P.C., Goya S., Perrin A., Lee R.T., Yadahalli S., Han A.X., Russell C.A., Schmutz S., Zaheri M., Kufner V., Huber M., Trkola A., Antwerpen M., Walter M.C., van der Werf S., Gambaro F., Behillil S., Enouf V., Donati F., Ustinova M., Rovite V., Klovins J., Savicka O., Wienecke-Baldacchino A.K., Ragimbeau C., Fournier G., Mossong J., Aberle S.W., Haukland M., Enkirch T., Advani A., Karlberg M.L., Lindsjo O.K., Broddesson S., Slavikova M., Lickova M., Klempa B., Staronova E., Ticha E., Szemes T., Rusnakova D., Stadler T., Quer J., Anton A., Andres C., Pinana M., Garcia-Cehic D., Pumarola T., Izopet J., Gioula G., Exindari M., Papa A., Chatzidimitriou D., Metallidis S., Pappa S., Macek M., Geryk J., Broz P., Briksi A., Hubacek P., Drevinek P., Zajac M., Kvapil P., Holub M., Kvapilova K., Novotny A., Kasny M., Klempt P., Vapalahti O., Smura T., Sironen T., Selhorst P., Anthony C., Arien K., Simon-Loriere E., Rabalski L., Bienkowska-Szewczyk K., Borges V., Isidro J., Gomes J.P., Guiomar R., Pechirra P., Costa I., Duarte S., Vieira L., Pyrc K., Zuckerman N.S., Turdikulova S., Abdullaev A., Dalimova D., Abdurakhimov A., Tagliabracci A., Alessandrini F., Melchionda F., Onofri V., Turchi C., Bagnarelli P., Menzo S., Caucci S., Di Sante L., Popa A., Genger J.-W., Agerer B., Lercher A., Endler L., Smyth M., Penz T., Schuster M., Senekowitsch M., Laine J., Bock C., Bergthaler A., Shevtsov A., Kalendar R., Ramanculov Y., Graf A., Muenchhoff M., Keppler O.T., Krebs S., Blum H., Marcello A., Licastro D., D'Agaro P., Laubscher F., Vidanovic D., Tesovic B., Volkening J., Clementi N., Mancini N., Rupnik M., Mahnic A., Walker A., Houwaart T., Wienemann T., Vasconcelos M.K., Strelow D., Jensen B.-E.O., Senff T., Hulse L., Adams O., Andree M., Hauka S., Feldt T., Keitel V., Kindgen-Milles D., Timm J., Pfeffer K., Dilthey A.T., Moore C., Ozdarendeli A., Pavel S.T.I., Yetiskin H., Aydin G., Holyavkin C., Uygut M.A., Cevik C., Shchetinin A., Gushchin V., Dinler-Doganay G., Doganay L., Kizilboga-Akgun T., Karacan I., Pancer K., Maes P., Marti-Carreras J., Wawina-Bokalanga T., Vanmechelen B., Thurmer A., Wedde M., Durrwald R., von Kleist M., Drechsel O., Wolff T., Fuchs S., Kmiecinski R., Michel J., Nitsche A., Casas I., Caballero M.I., Zaballos A., Jimenez P., Jimenez M., Fernandez S.M., Fernandez S.V., de la Plaza I.C., Fadeev A., Ivanova A., Sergeeva M., Stefanelli P., Estee Torok M., Hall G., da Silva Filipe A., Turtle L., Afifi S., McCluggage K., Beer R., Ledesma J., Maksimovic J., Spellman K., Hamilton W.L., Marchbank A., Southgate J.A., Underwood A., Taylor B., Yeats C., Abudahab K., Gemmell M.R., Eccles R., Lucaci A., Nelson C.A., Rainbow L., Whitehead M., Gregory R., Haldenby S., Paterson S., Hughes M.A., Curran M.D., Baker D., Tucker R., Green L.R., Feltwell T., Halstead F.D., Wyles M., Jahun A.S., Ahmad S.S.Y., Georgana I., Goodfellow I., Yakovleva A., Meredith L.W., Gavriil A., Awan A.R., Fisher C., Edgeworth J., Lynch J., Moore N., Williams R., Kidd S.P., Cortes N., Brunker K., McCrone J.T., Quick J., Duckworth N., Walsh S., Sloan T., Ludden C., George R.P., Eltringham G., Brown J.R., Aranday-Cortes E., Shepherd J.G., Hughes J., Li K.K., Williams T.C., Johnson N., Jesudason N., Mair D., Thomson E., Shah R., Parr Y.A., Carmichael S., Robertson D.L., Nomikou K., Broos A., Niebel M., Smollett K., Tong L., Miah S., Wittner A., Phillips N., Payne B., Dewar R., Holmes A., Bolt F., Price J.R., Mookerjee S., Sethi D.K., Potter W., Stanley R., Prakash R., Dervisevic S., Graham J.C., Nelson A., Smith D., Young G.R., Yew W.C., Todd J.A., Trebes A., Andersson M., Bull M., Watkins J., Birchley A., Gatica-Wilcox B., Gilbert L., Kumziene-Summerhayes S., Rey S., Chauhan A., Butcher E., Bicknell K., Elliott S., Glaysher S., Lackenby A., Bibby D., Platt S., Mohamed H., Machin N.W., Mbisa J.L., Evans J., Perry M., Pacchiarini N., Corden S., Adams A.G., Gaskin A., Coombs J., Graham L.J., Cottrell S., Morgan M., Gifford L., Kolyva A., Rudder S.J., Trotter A.J., Mather A.E., Aydin A., Page A.J., Kay G.L., de Oliveira Martins L., Yasir M., Alikhan N.-F., Thomson N.M., Gilroy R., Kingsley R.A., O'Grady J., Gutierrez A.V., Diaz M., Viet T.L., Tedim A.P., Adriaenssens E.M., Patrick Mcclure C., Sang F., Clark G., Howson-Wells H.C., Debebe J., Ball J., Chappell J., Khakh M., Carlile M., Loose M., Lister M.M., Holmes N., Tsoleridis T., Fleming V.M., Wright V., Smith W., Gallagher M.D., Parker M., Partridge D.G., Evans C., Baker P., Essex S., Liggett S., Keeley A.J., Bashton M., Rooke S., Dervisavic S., Meader E.J., Lopez C.E.B., Angyal A., Kristiansen M., Tutill H.J., Findlay J., Mestek-Boukhibar L., Forrest L., Dyal P., Williams R.J., Panchbhaya Y., Williams C.A., Roy S., Pandey S., Stockton J., Loman N.J., Poplawski R., Nicholls S., Rowe W.P.M., Khokhar F., Pinckert M.L., Hosmillo M., Chaudhry Y., Caller L.G., Davidson R.K., Griffith L., Rambaut A., Jackson B., Colquhoun R., Hill V., Nichols J., Asamaphan P., Darby A., Jackson K.A., Iturriza-Gomara M., Vamos E.E., Green A., Aanensen D., Bonsall D., Buck D., Macintyre-Cockett G., de Cesare M., Pybus O., Golubchik T., Scarlett G., Loveson K.F., Robson S.C., Beckett A., Lindsey B., Groves D.C., Parsons P.J., McHugh M.P., Barnes J.D., Manso C.F., Grammatopoulos D., Menger K.E., Harrison E., Gunson R., Peacock S.J., Gonzalez G., Carr M., Mihaela L., Popovici O., Brytting M., Bresner C., Fuller W., Workman T., Mentis A.F., Kossyvakis A., Karamitros T., Pogka V., Kalliaropoulos A., Horefti E., Kontou A., Martinez-Gonzalez B., Labropoulou V., Voulgari-Kokota A., Evangelidou M., Bizta P., Belimezi M., Lambrechts L., Doymaz M.Z., Yazici M.K., Cetin N.S., Karaaslan E., Kallio-Kokko H., Virtanen J., Suvanto M., Nguyen P.T., Ellonen P., Hannula S., Kangas H., Sreenu V.B., Burian K., Terhes G., Gombos K., Gyenesei A., Urban P., Herczeg R., Jakab F., Kemenesi G., Toth G.E., Somogyi B., Zana B., Zeghbib S., Kuczmog A., Foldes F., Lanszki Z., Madai M., Papp H., Pereszlenyi C.I., Babinszky G.C., Dudas G., Csoma E., Abou Tayoun A.N., Alsheikh-Ali A.A., Loney T., Nowotny N., Abdul-Wahab O., Gonzalez-Candelas F., Andersen M.H., Taylor S., MARTI CARRERAS, Joan, Vanmechelen, Bert, Wawina, Tony, Medical Microbiology and Infection Prevention, AII - Infectious diseases, WHO European Region Sequencing Lab, GISAID EpiCoV Grp, Erik, Alm, Eeva K, Broberg, Thomas, Connor, Emma B, Hodcroft, Andrey B, Komissarov, Sebastian, Maurer-Stroh, Angeliki, Melidou, Richard A, Neher, Áine, O’Toole, Dmitriy, Pereyaslov, WHO European Region sequencing laboratories and GISAID EpiCoV group (Niko Beerenwinkel, The, Posada-Céspedes, Susana, Philipp, Kim, Jablonski, Falé Ferreira, Pedro, Topolsky, Ivan, Avšičžupanc, Tatjana, Korva, Miša, Poljak, Mario, Zakotnik, Samo, Tomaž, Zorec, Mark, Bragstad, Karoline, Hungnes, Olav, Stene-Johansen, Kathrine, Reusken, Chantal, Meijer, Adam, Vennema, Harry, Ruiz-Roldán, Lidia, Alma Bracho, María, García-González, Neri, Chiner-Oms, Álvaro, Cancino-Muñoz, Irving, Comas, Iñaki, A Goig, Galo, Torres-Puente, Manuela, G López, Mariana, Martínez-Priego, Llúcia, D’Auria, Giuseppe, LoretoFerrús-Abad, de Marco, Griselda, Galan-Vendrell, Inmaculada, Carbó-Ramirez, Sandra, Ruíz-Hueso, Paula, Coscollá, Mireia, Polackova, Katerina, Kramna, Lenka, Cinek, Ondrej, Richter, Jan, Krashias, George, Tryfonos, Christina, Bashiardes, Stavro, Koptides, Dana, Christodoulou, Christina, Bartolini, Barbara, Em Gruber, Cesare, Di Caro, Antonino, Castilletti, Concetta, Stefani, Fabrizio, Giordana Rimoldi, Sara, Romeri, Francesca, Salerno, Franco, Polesello, Stefano, Nagy, Alexander, Jirincova, Helena, Vecerova, Jaromira, Novakova, Ludmila, Cordey, Samuel, Murtskhvaladze, Marine, Kotaria, Nato, Schär, Tobia, Beisel, Christian, Vugrek, Oliver, Rokić, Filip, Trgovecgreif, Lovro, Jurak, Igor, Rukavina, Tomislav, Sučić, Neven, Schønning, Kristian, M Karst, Søren, H Kirkegaard, Rasmu, Y Michaelsen, Thoma, Aa Sørensen, Emil, Knutson, Simon, Brandt, Jakob, Le-Quy, Vang, Sørensen, Trine, Petersen, Celine, Schou Pedersen, Martin, Løkkegaard Larsen, Sanne, Nielsine Skov, Marianne, Rasmussen, Morten, Fonager, Jannik, Fomsgaard, Ander, Amirovich Maksyutov, Rinat, Vasil’Evna Gavrilova, Elena, Victorovich Pyankov, Oleg, Alexandrovich Bodnev, Sergey, Vladimirovna Tregubchak, Tatyana, Nikolayevich Shvalov, Alexander, Victorovich Antonets, Deni, Cristina Resende, Paola, Goya, Stephanie, Perrin, Amandine, Tc Lee, Raphael, Yadahalli, Shilpa, X Han, Alvin, A Russell, Colin, Schmutz, Stefan, Zaheri, Maryam, Kufner, Verena, Huber, Michael, Trkola, Alexandra, Antwerpen, Marku, C Walter, Mathia, van der Werf, Sylvie, Gambaro, Fabiana, Behillil, Sylvie, Enouf, Vincent, Donati, Flora, Ustinova, Monta, Rovite, Vita, Klovins, Jani, Savicka, Oksana, K Wienecke-Baldacchino, Anke, Ragimbeau, Catherine, Fournier, Guillaume, Mossong, Joël, W Aberle, Stephan, Haukland, Mattia, Enkirch, Theresa, Advani, Abdolreza, Lind Karlberg, Maria, Karlsson Lindsjö, Oskar, Broddesson, Sandra, Sláviková, Monika, Ličková, Martina, Klempa, Bori, Staroňová, Edita, Tichá, Elena, Szemes, Tomáš, Rusňáková, Diana, Stadler, Tanja, Quer, Josep, Anton, Andre, Andres, Cristina, Piñana, Maria, Garcia-Cehic, Damir, Pumarola, Toma, Izopet, Jacque, Gioula, Georgia, Exindari, Maria, Papa, Anna, Chatzidimitriou, Dimitrio, Metallidis, Symeon, Pappa, Stella, Macek Jr, Milan, Geryk, Jan, Brož, Petr, Briksí, Aleš, Hubáček, Petr, Dřevínek, Pavel, Zajac, Miroslav, Kvapil, Petr, Holub, Michal, Kvapilová, Kateřina, Novotný, Adam, Kašný, Martin, Klempt, Petr, Vapalahti, Olli, Smura, Teemu, Sironen, Tarja, Selhorst, Philippe, Anthony, Colin, Ariën, Kevin, Simon-Loriere, Etienne, Rabalski, Lukasz, Bienkowska-Szewczyk, Krystyna, Borges, Vítor, Isidro, Joana, Paulo Gomes, João, Guiomar, Raquel, Pechirra, Pedro, Costa, Inê, Duarte, Sílvia, Vieira, Luí, Pyrc, Krzysztof, S Zuckerman, Neta, Turdikulova, Shahlo, Abdullaev, Alisher, Dalimova, Dilbar, Abdurakhimov, Abror, Tagliabracci, Adriano, Alessandrini, Federica, Melchionda, Filomena, Onofri, Valerio, Turchi, Chiara, Bagnarelli, Patrizia, Menzo, Stefano, Caucci, Sara, Di Sante, Laura, Popa, Alexandra, Genger, Jakob-Wendelin, Agerer, Benedikt, Lercher, Alexander, Endler, Luka, Smyth, Mark, Penz, Thoma, Schuster, Michael, Senekowitsch, Martin, Laine, Jan, Bock, Christoph, Bergthaler, Andrea, Shevtsov, Alexandr, Kalendar, Ruslan, Ramanculov, Yerlan, Graf, Alexander, Muenchhoff, Maximilian, T Keppler, Oliver, Krebs, Stefan, Blum, Helmut, Marcello, Alessandro, Licastro, Danilo, D’Agaro, Pierlanfranco, Laubscher, Florian, Vidanovic, Dejan, Tesovic, Bojana, Volkening, Jeremy, Clementi, Nicola, Mancini, Nicasio, Rupnik, Maja, Mahnic, Aleksander, Walker, Andrea, Houwaart, Torsten, Wienemann, Tobia, Kohns Vasconcelos, Malte, Strelow, Daniel, Ole Jensen, Björn-Erik, Senff, Tina, Hülse, Lisanna, Adams, Ortwin, Andree, Marcel, Hauka, Sandra, Feldt, Torsten, Keitel, Verena, Kindgen-Milles, Detlef, Timm, Jörg, Pfeffer, Klau, T Dilthey, Alexander, Moore, Catherine, Ozdarendeli, Aykut, Terkis Islam Pavel, Shaikh, Yetiskin, Hazel, Aydin, Gunsu, Holyavkin, Can, Ali Uygut, Muhammet, Cevik, Ceren, Shchetinin, Alexey, Gushchin, Vladimir, Dinler-Doganay, Gizem, Doganay, Levent, Kizilboga-Akgun, Tugba, Karacan, Ilker, Pancer, Katarzyna, Maes, Piet, Martí-Carreras, Joan, Wawina-Bokalanga, Tony, Thürmer, Andrea, Wedde, Marianne, Dürrwald, Ralf, Von Kleist, Max, Drechsel, Oliver, Wolff, Thorsten, Fuchs, Stephan, Kmiecinski, Rene, Michel, Janine, Nitsche, Andrea, Casas, Inmaculada, Iglesias Caballero, María, Zaballos, Ángel, Jiménez, Pilar, Jiménez, Mercede, Monzón Fernández, Sara, Varona Fernández, Sarai, Cuesta De La Plaza, Isabel, Fadeev, Artem, Ivanova, Anna, Sergeeva, Mariia, Stefanelli, Paola, Estee Torok, M, Hall, Grant, da Silva Filipe, Ana, Turtle, Lance, Afifi, Safiah, Mccluggage, Kathryn, Beer, Robert, Ledesma, Juan, Maksimovic, Joshua, Spellman, Karla, L Hamilton, William, Marchbank, Angela, Alexander Southgate, Joel, Underwood, Anthony, Taylor, Ben, Yeats, Corin, Abudahab, Khalil, R Gemmell, Matthew, Eccles, Richard, Lucaci, Anita, Abigail Nelson, Charlotte, Rainbow, Lucille, Whitehead, Mark, Gregory, Richard, Haldenby, Sam, Paterson, Steve, A Hughes, Margaret, D Curran, Martin, Baker, David, Tucker, Rachel, R Green, Luke, Feltwell, Theresa, D Halstead, Fenella, Wyles, Matthew, S Jahun, Aminu, Y Ahmad, Shazaad S, Georgana, Iliana, Goodfellow, Ian, Yakovleva, Anna, W Meredith, Luke, Gavriil, Artemi, Raza Awan, Ali, Fisher, Chloe, Jonathan, European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), Cardiff University, Public Health Wales [Cardiff, Royaume uni], University of Basel (Unibas), Research Institute of Influenza, St. Petersburg, Russia, Agency for science, technology and research [Singapore] (A*STAR), National University of Singapore (NUS), University of Edinburgh, WHO Regional Office for Europe [Copenhagen], We gratefully acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiCoV Database used in the phylogenetic analysis. We gratefully acknowledge all the staff working with sample collection, sample preparation, sequencing, data analysis and data sharing in all laboratories in the WHO European Region for making this work possible, The WHO European Region sequencing laboratories and GISAID EpiCoV group*: Niko Beerenwinkel, Susana Posada-Céspedes, Kim Philipp Jablonski, Pedro Falé Ferreira, Ivan Topolsky, Tatjana Avšič-Županc, Miša Korva, Mario Poljak, Samo Zakotnik, Tomaž Mark Zorec, Karoline Bragstad, Olav Hungnes, Kathrine Stene-Johansen, Chantal Reusken, Adam Meijer, Harry Vennema, Lidia Ruiz-Roldán, María Alma Bracho, Neris García-González, Álvaro Chiner-Oms, Irving Cancino-Muñoz, Iñaki Comas, Galo A Goig, Manuela Torres-Puente, Mariana G López, Llúcia Martínez-Priego, Giuseppe D'Auria, Paula Ruíz-Hueso, Loreto Ferrús-Abad, Griselda de Marco, Inmaculada Galan-Vendrell, Sandra Carbó-Ramirez, Paula Ruiz-Rodriguez, Mireia Coscollá, Katerina Polackova, Lenka Kramna, Ondrej Cinek, Jan Richter, George Krashias, Christina Tryfonos, Stavros Bashiardes, Dana Koptides, Christina Christodoulou, Barbara Bartolini, Cesare Em Gruber, Antonino Di Caro, Concetta Castilletti, Fabrizio Stefani, Sara Giordana Rimoldi, Francesca Romeri, Franco Salerno, Stefano Polesello, Alexander Nagy, Helena Jirincova, Jaromira Vecerova, Ludmila Novakova, Samuel Cordey, Marine Murtskhvaladze, Nato Kotaria, Tobias Schär, Christian Beisel, Oliver Vugrek, Filip Rokić, Lovro Trgovec-Greif, Igor Jurak, Tomislav Rukavina, Neven Sučić, Kristian Schønning, Søren M Karst, Rasmus H Kirkegaard, Thomas Y Michaelsen, Emil Aa Sørensen, Simon Knutson, Jakob Brandt, Vang Le-Quy, Trine Sørensen, Celine Petersen, Martin Schou Pedersen, Sanne Løkkegaard Larsen, Marianne Nielsine Skov, Morten Rasmussen, Jannik Fonager, Anders Fomsgaard, Rinat Amirovich Maksyutov, Elena Vasil'Evna Gavrilova, Oleg Victorovich Pyankov, Sergey Alexandrovich Bodnev, Tatyana Vladimirovna Tregubchak, Alexander Nikolayevich Shvalov, Denis Victorovich Antonets, Paola Cristina Resende, Stephanie Goya, Amandine Perrin, Raphael Tc Lee, Shilpa Yadahalli, Alvin X Han, Colin A Russell, Stefan Schmutz, Maryam Zaheri, Verena Kufner, Michael Huber, Alexandra Trkola, Markus Antwerpen, Mathias C Walter, Sylvie van der Werf, Fabiana Gambaro, Sylvie Behillil, Vincent Enouf, Flora Donati, Monta Ustinova, Vita Rovite, Janis Klovins, Oksana Savicka, Anke K Wienecke-Baldacchino, Catherine Ragimbeau, Guillaume Fournier, Joël Mossong, Stephan W Aberle, Mattias Haukland, Theresa Enkirch, Abdolreza Advani, Maria Lind Karlberg, Oskar Karlsson Lindsjö, Sandra Broddesson, Monika Sláviková, Martina Ličková, Boris Klempa, Edita Staroňová, Elena Tichá, Tomáš Szemes, Diana Rusňáková, Tanja Stadler, Josep Quer, Andres Anton, Cristina Andres, Maria Piñana, Damir Garcia-Cehic, Tomas Pumarola, Jacques Izopet, Georgia Gioula, Maria Exindari, Anna Papa, Dimitrios Chatzidimitriou, Symeon Metallidis, Stella Pappa, Milan Macek Jr, Jan Geryk, Petr Brož, Aleš Briksí, Petr Hubáček, Pavel Dřevínek, Miroslav Zajac, Petr Kvapil, Michal Holub, Kateřina Kvapilová, Adam Novotný, Martin Kašný, Petr Klempt, Olli Vapalahti, Teemu Smura, Tarja Sironen, Philippe Selhorst, Colin Anthony, Kevin Ariën, Etienne Simon-Loriere, Lukasz Rabalski, Krystyna Bienkowska-Szewczyk, Vítor Borges, Joana Isidro, João Paulo Gomes, Raquel Guiomar, Pedro Pechirra, Inês Costa, Sílvia Duarte, Luís Vieira, Krzysztof Pyrc, Neta S Zuckerman, Shahlo Turdikulova, Alisher Abdullaev, Dilbar Dalimova, Abror Abdurakhimov, Adriano Tagliabracci, Federica Alessandrini, Filomena Melchionda, Valerio Onofri, Chiara Turchi, Patrizia Bagnarelli, Stefano Menzo, Sara Caucci, Laura Di Sante, Alexandra Popa, Jakob-Wendelin Genger, Benedikt Agerer, Alexander Lercher, Lukas Endler, Mark Smyth, Thomas Penz, Michael Schuster, Martin Senekowitsch, Jan Laine, Christoph Bock, Andreas Bergthaler, Alexandr Shevtsov, Ruslan Kalendar, Yerlan Ramanculov, Alexander Graf, Maximilian Muenchhoff, Oliver T Keppler, Stefan Krebs, Helmut Blum, Alessandro Marcello, Danilo Licastro, Pierlanfranco D'Agaro, Florian Laubscher, Dejan Vidanovic, Bojana Tesovic, Jeremy Volkening, Nicola Clementi, Nicasio Mancini, Maja Rupnik, Aleksander Mahnic, Andreas Walker, Torsten Houwaart, Tobias Wienemann, Malte Kohns Vasconcelos, Daniel Strelow, Björn-Erik Ole Jensen, Tina Senff, Lisanna Hülse, Ortwin Adams, Marcel Andree, Sandra Hauka, Torsten Feldt, Verena Keitel, Detlef Kindgen-Milles, Jörg Timm, Klaus Pfeffer, Alexander T Dilthey, Catherine Moore, Aykut Ozdarendeli, Shaikh Terkis Islam Pavel, Hazel Yetiskin, Gunsu Aydin, Can Holyavkin, Muhammet Ali Uygut, Ceren Cevik, Alexey Shchetinin, Vladimir Gushchin, Gizem Dinler-Doganay, Levent Doganay, Tugba Kizilboga-Akgun, Ilker Karacan, Katarzyna Pancer, Piet Maes, Joan Martí-Carreras, Tony Wawina-Bokalanga, Bert Vanmechelen, Andrea Thürmer, Marianne Wedde, Ralf Dürrwald, Max Von Kleist, Oliver Drechsel, Thorsten Wolff, Stephan Fuchs, Rene Kmiecinski, Janine Michel, Andreas Nitsche, Inmaculada Casas, María Iglesias Caballero, Ángel Zaballos, Pilar Jiménez, Mercedes Jiménez, Sara Monzón Fernández, Sarai Varona Fernández, Isabel Cuesta De La Plaza, Artem Fadeev, Anna Ivanova, Mariia Sergeeva, Paola Stefanelli, M Estee Torok, Grant Hall, Ana da Silva Filipe, Lance Turtle, Safiah Afifi, Kathryn Mccluggage, Robert Beer, Juan Ledesma, Joshua Maksimovic, Karla Spellman, William L Hamilton, Angela Marchbank, Joel Alexander Southgate, Anthony Underwood, Ben Taylor, Corin Yeats, Khalil Abudahab, Matthew R Gemmell, Richard Eccles, Anita Lucaci, Charlotte Abigail Nelson, Lucille Rainbow, Mark Whitehead, Richard Gregory, Sam Haldenby, Steve Paterson, Margaret A Hughes, Martin D Curran, David Baker, Rachel Tucker, Luke R Green, Theresa Feltwell, Fenella D Halstead, Matthew Wyles, Aminu S Jahun, Shazaad S Y Ahmad, Iliana Georgana, Ian Goodfellow, Anna Yakovleva, Luke W Meredith, Artemis Gavriil, Ali Raza Awan, Chloe Fisher, Jonathan Edgeworth, Jessica Lynch, Nathan Moore, Rebecca Williams, Stephen P Kidd, Nicholas Cortes, Kirstyn Brunker, John T Mccrone, Joshua Quick, Nichola Duckworth, Sarah Walsh, Tim Sloan, Catherine Ludden, Ryan P George, Gary Eltringham, Julianne R Brown, Elihu Aranday-Cortes, James G Shepherd, Joseph Hughes, Kathy K Li, Thomas C Williams, Natasha Johnson, Natasha Jesudason, Daniel Mair, Emma Thomson, Rajiv Shah, Yasmin A Parr, Stephen Carmichael, David L Robertson, Kyriaki Nomikou, Alice Broos, Marc Niebel, Katherine Smollett, Lily Tong, Shahjahan Miah, Anita Wittner, Nicole Phillips, Brendan Payne, Rebecca Dewar, Alison Holmes, Frances Bolt, James R Price, Siddharth Mookerjee, Dheeraj K Sethi, Will Potter, Rachael Stanley, Reenesh Prakash, Samir Dervisevic, Jonathan Clive Graham, Andrew Nelson, Darren Smith, Gregory R Young, Wen Chyin Yew, John A Todd, Amy Trebes, Monique Andersson, Matthew Bull, Joanne Watkins, Alec Birchley, Bree Gatica-Wilcox, Lauren Gilbert, Sara Kumžiene-Summerhayes, Sara Rey, Anoop Chauhan, Ethan Butcher, Kelly Bicknell, Scott Elliott, Sharon Glaysher, Angie Lackenby, David Bibby, Steven Platt, Hodan Mohamed, Nicholas William Machin, Jean Lutamyo Mbisa, Jonathan Evans, Malorie Perry, Nicole Pacchiarini, Sally Corden, Alexander Geraint Adams, Amy Gaskin, Jason Coombs, Lee John Graham, Simon Cottrell, Mari Morgan, Laura Gifford, Anastasia Kolyva, Steven John Rudder, Alexander J Trotter, Alison E Mather, Alp Aydin, Andrew J Page, Gemma L Kay, Leonardo de Oliveira Martins, Muhammad Yasir, Nabil-Fareed Alikhan, Nicholas M Thomson, Rachel Gilroy, Robert A Kingsley, Justin O'Grady, Ana Victoria Gutierrez, Maria Diaz, Thanh Le Viet, Ana P Tedim, Evelien M Adriaenssens, C Patrick Mcclure, Christopher Moore, Fei Sang, Gemma Clark, Hannah C Howson-Wells, Johnny Debebe, Jonathan Ball, Joseph Chappell, Manjinder Khakh, Matthew Carlile, Matthew Loose, Michelle M Lister, Nadine Holmes, Theocharis Tsoleridis, Vicki M Fleming, Victoria Wright, Wendy Smith, Michael D Gallagher, Matthew Parker, David G Partridge, Cariad Evans, Paul Baker, Sarah Essex, Steven Liggett, Alexander J Keeley, Matthew Bashton, Stefan Rooke, Samir Dervisevic, Emma Jane Meader, Carlos Enrique Balcazar Lopez, Adrienn Angyal, Mark Kristiansen, Helena J Tutill, Jacqueline Findlay, Lamia Mestek-Boukhibar, Leysa Forrest, Patricia Dyal, Rachel J Williams, Yasmin Panchbhaya, Charlotte A Williams, Sunando Roy, Sarojini Pandey, Jo Stockton, Nicholas J Loman, Radoslaw Poplawski, Samuel Nicholls, W P M Rowe, Fahad Khokhar, Malte Lars Pinckert, Myra Hosmillo, Yasmin Chaudhry, Laura G Caller, Rose K Davidson, Luke Griffith, Andrew Rambaut, Ben Jackson, Rachel Colquhoun, Verity Hill, Jenna Nichols, Patawee Asamaphan, Alistair Darby, Kathryn A Jackson, Miren Iturriza-Gomara, Ecaterina Edith Vamos, Angie Green, David Aanensen, David Bonsall, David Buck, George Macintyre-Cockett, Mariateresa de Cesare, Oliver Pybus, Tanya Golubchik, Garry Scarlett, Katie F Loveson, Samuel C Robson, Angela Beckett, Benjamin Lindsey, Danielle C Groves, Paul J Parsons, Martin P Mchugh, James Daniel Barnes, Carmen F Manso, Dimitris Grammatopoulos, Katja Elisabeth Menger, Ewan Harrison, Rory Gunson, Sharon J Peacock, Gabriel Gonzalez, Michael Carr, Lazar Mihaela, Odette Popovici, Mia Brytting, Catherine Bresner, William Fuller, Trudy Workman, Andreas F Mentis, Athanasios Kossyvakis, Timokratis Karamitros, Vasiliki Pogka, Antonios Kalliaropoulos, Elina Horefti, Aspasia Kontou, Beatriz Martinez-Gonzalez, Voula Labropoulou, Androniki Voulgari-Kokota, Maria Evangelidou, Panagiota Bizta, Maria Belimezi, Laurens Lambrechts, Mehmet Z Doymaz, Merve Kalkan Yazici, Nesibe S Cetin, Elif Karaaslan, Hannimari Kallio-Kokko, Jenni Virtanen, Maija Suvanto, Phuoc Truong Nguyen, Pekka Ellonen, Sari Hannula, Harri Kangas, Vattipally B Sreenu, Katalin Burián, Gabriella Terhes, Katalin Gombos, Attila Gyenesei, Péter Urbán, Róbert Herczeg, Ferenc Jakab, Gábor Kemenesi, Gábor Endre Tóth, Balázs Somogyi, Brigitta Zana, Safia Zeghbib, Anett Kuczmog, Fanni Földes, Zsófia Lanszki, Mónika Madai, Henrietta Papp, Ágnes Nagy, Csaba István Pereszlényi, Gergely Csaba Babinszky, Gábor Dudás, Eszter Csoma, Ahmad N Abou Tayoun, Alawi A Alsheikh-Ali, Tom Loney, Norbert Nowotny, Osama Abdul-Wahab, Fernando Gonzalez-Candelas, Martin H Andersen, Sarah Taylor, Comas, Iñaki [0000-0001-5504-9408], Alm, E., Broberg, E. K., Connor, T., Hodcroft, E. B., Komissarov, A. B., Maurer-Stroh, S., Melidou, A., Neher, R. A., O'Toole, A., Pereyaslov, D., Beerenwinkel, N., Posada-Cespedes, S., Jablonski, K. P., Ferreira, P. F., Topolsky, I., Avsic-Zupanc, T., Korva, M., Poljak, M., Zakotnik, S., Zorec, T. M., Bragstad, K., Hungnes, O., Stene-Johansen, K., Reusken, C., Meijer, A., Vennema, H., Ruiz-Roldan, L., Bracho, M. A., Garcia-Gonzalez, N., Chiner-Oms, A., Cancino-Munoz, I., Comas, I., Goig, G. A., Torres-Puente, M., Lopez, M. G., Martinez-Priego, L., D'Auria, G., Ruiz-Hueso, P., Ferrus-Abad, L., de Marco, G., Galan-Vendrell, I., Carbo-Ramirez, S., Ruiz-Rodriguez, P., Coscolla, M., Polackova, K., Kramna, L., Cinek, O., Richter, J., Krashias, G., Tryfonos, C., Bashiardes, S., Koptides, D., Christodoulou, C., Bartolini, B., Gruber, C. E., Di Caro, A., Castilletti, C., Stefani, F., Rimoldi, S. G., Romeri, F., Salerno, F., Polesello, S., Nagy, A., Jirincova, H., Vecerova, J., Novakova, L., Cordey, S., Murtskhvaladze, M., Kotaria, N., Schar, T., Beisel, C., Vugrek, O., Rokic, F., Trgovec-Greif, L., Jurak, I., Rukavina, T., Sucic, N., Schonning, K., Karst, S. M., Kirkegaard, R. H., Michaelsen, T. Y., Sorensen, E. A., Knutson, S., Brandt, J., Le-Quy, V., Sorensen, T., Petersen, C., Pedersen, M. S., Larsen, S. L., Skov, M. N., Rasmussen, M., Fonager, J., Fomsgaard, A., Maksyutov, R. A., Gavrilova, E. V., Pyankov, O. V., Bodnev, S. A., Tregubchak, T. V., Shvalov, A. N., Antonets, D. V., Resende, P. C., Goya, S., Perrin, A., Lee, R. T., Yadahalli, S., Han, A. X., Russell, C. A., Schmutz, S., Zaheri, M., Kufner, V., Huber, M., Trkola, A., Antwerpen, M., Walter, M. C., van der Werf, S., Gambaro, F., Behillil, S., Enouf, V., Donati, F., Ustinova, M., Rovite, V., Klovins, J., Savicka, O., Wienecke-Baldacchino, A. K., Ragimbeau, C., Fournier, G., Mossong, J., Aberle, S. W., Haukland, M., Enkirch, T., Advani, A., Karlberg, M. L., Lindsjo, O. K., Broddesson, S., Slavikova, M., Lickova, M., Klempa, B., Staronova, E., Ticha, E., Szemes, T., Rusnakova, D., Stadler, T., Quer, J., Anton, A., Andres, C., Pinana, M., Garcia-Cehic, D., Pumarola, T., Izopet, J., Gioula, G., Exindari, M., Papa, A., Chatzidimitriou, D., Metallidis, S., Pappa, S., Macek, M., Geryk, J., Broz, P., Briksi, A., Hubacek, P., Drevinek, P., Zajac, M., Kvapil, P., Holub, M., Kvapilova, K., Novotny, A., Kasny, M., Klempt, P., Vapalahti, O., Smura, T., Sironen, T., Selhorst, P., Anthony, C., Arien, K., Simon-Loriere, E., Rabalski, L., Bienkowska-Szewczyk, K., Borges, V., Isidro, J., Gomes, J. P., Guiomar, R., Pechirra, P., Costa, I., Duarte, S., Vieira, L., Pyrc, K., Zuckerman, N. S., Turdikulova, S., Abdullaev, A., Dalimova, D., Abdurakhimov, A., Tagliabracci, A., Alessandrini, F., Melchionda, F., Onofri, V., Turchi, C., Bagnarelli, P., Menzo, S., Caucci, S., Di Sante, L., Popa, A., Genger, J. -W., Agerer, B., Lercher, A., Endler, L., Smyth, M., Penz, T., Schuster, M., Senekowitsch, M., Laine, J., Bock, C., Bergthaler, A., Shevtsov, A., Kalendar, R., Ramanculov, Y., Graf, A., Muenchhoff, M., Keppler, O. T., Krebs, S., Blum, H., Marcello, A., Licastro, D., D'Agaro, P., Laubscher, F., Vidanovic, D., Tesovic, B., Volkening, J., Clementi, N., Mancini, N., Rupnik, M., Mahnic, A., Walker, A., Houwaart, T., Wienemann, T., Vasconcelos, M. K., Strelow, D., Jensen, B. -E. O., Senff, T., Hulse, L., Adams, O., Andree, M., Hauka, S., Feldt, T., Keitel, V., Kindgen-Milles, D., Timm, J., Pfeffer, K., Dilthey, A. T., Moore, C., Ozdarendeli, A., Pavel, S. T. I., Yetiskin, H., Aydin, G., Holyavkin, C., Uygut, M. A., Cevik, C., Shchetinin, A., Gushchin, V., Dinler-Doganay, G., Doganay, L., Kizilboga-Akgun, T., Karacan, I., Pancer, K., Maes, P., Marti-Carreras, J., Wawina-Bokalanga, T., Vanmechelen, B., Thurmer, A., Wedde, M., Durrwald, R., von Kleist, M., Drechsel, O., Wolff, T., Fuchs, S., Kmiecinski, R., Michel, J., Nitsche, A., Casas, I., Caballero, M. I., Zaballos, A., Jimenez, P., Jimenez, M., Fernandez, S. M., Fernandez, S. V., de la Plaza, I. C., Fadeev, A., Ivanova, A., Sergeeva, M., Stefanelli, P., Estee Torok, M., Hall, G., da Silva Filipe, A., Turtle, L., Afifi, S., Mccluggage, K., Beer, R., Ledesma, J., Maksimovic, J., Spellman, K., Hamilton, W. L., Marchbank, A., Southgate, J. A., Underwood, A., Taylor, B., Yeats, C., Abudahab, K., Gemmell, M. R., Eccles, R., Lucaci, A., Nelson, C. A., Rainbow, L., Whitehead, M., Gregory, R., Haldenby, S., Paterson, S., Hughes, M. A., Curran, M. D., Baker, D., Tucker, R., Green, L. R., Feltwell, T., Halstead, F. D., Wyles, M., Jahun, A. S., Ahmad, S. S. Y., Georgana, I., Goodfellow, I., Yakovleva, A., Meredith, L. W., Gavriil, A., Awan, A. R., Fisher, C., Edgeworth, J., Lynch, J., Moore, N., Williams, R., Kidd, S. P., Cortes, N., Brunker, K., Mccrone, J. T., Quick, J., Duckworth, N., Walsh, S., Sloan, T., Ludden, C., George, R. P., Eltringham, G., Brown, J. R., Aranday-Cortes, E., Shepherd, J. G., Hughes, J., Li, K. K., Williams, T. C., Johnson, N., Jesudason, N., Mair, D., Thomson, E., Shah, R., Parr, Y. A., Carmichael, S., Robertson, D. L., Nomikou, K., Broos, A., Niebel, M., Smollett, K., Tong, L., Miah, S., Wittner, A., Phillips, N., Payne, B., Dewar, R., Holmes, A., Bolt, F., Price, J. R., Mookerjee, S., Sethi, D. K., Potter, W., Stanley, R., Prakash, R., Dervisevic, S., Graham, J. C., Nelson, A., Smith, D., Young, G. R., Yew, W. C., Todd, J. A., Trebes, A., Andersson, M., Bull, M., Watkins, J., Birchley, A., Gatica-Wilcox, B., Gilbert, L., Kumziene-Summerhayes, S., Rey, S., Chauhan, A., Butcher, E., Bicknell, K., Elliott, S., Glaysher, S., Lackenby, A., Bibby, D., Platt, S., Mohamed, H., Machin, N. W., Mbisa, J. L., Evans, J., Perry, M., Pacchiarini, N., Corden, S., Adams, A. G., Gaskin, A., Coombs, J., Graham, L. J., Cottrell, S., Morgan, M., Gifford, L., Kolyva, A., Rudder, S. J., Trotter, A. J., Mather, A. E., Aydin, A., Page, A. J., Kay, G. L., de Oliveira Martins, L., Yasir, M., Alikhan, N. -F., Thomson, N. M., Gilroy, R., Kingsley, R. A., O'Grady, J., Gutierrez, A. V., Diaz, M., Viet, T. L., Tedim, A. P., Adriaenssens, E. M., Patrick Mcclure, C., Sang, F., Clark, G., Howson-Wells, H. C., Debebe, J., Ball, J., Chappell, J., Khakh, M., Carlile, M., Loose, M., Lister, M. M., Holmes, N., Tsoleridis, T., Fleming, V. M., Wright, V., Smith, W., Gallagher, M. D., Parker, M., Partridge, D. G., Evans, C., Baker, P., Essex, S., Liggett, S., Keeley, A. J., Bashton, M., Rooke, S., Dervisavic, S., Meader, E. J., Lopez, C. E. B., Angyal, A., Kristiansen, M., Tutill, H. J., Findlay, J., Mestek-Boukhibar, L., Forrest, L., Dyal, P., Williams, R. J., Panchbhaya, Y., Williams, C. A., Roy, S., Pandey, S., Stockton, J., Loman, N. J., Poplawski, R., Nicholls, S., Rowe, W. P. M., Khokhar, F., Pinckert, M. L., Hosmillo, M., Chaudhry, Y., Caller, L. G., Davidson, R. K., Griffith, L., Rambaut, A., Jackson, B., Colquhoun, R., Hill, V., Nichols, J., Asamaphan, P., Darby, A., Jackson, K. A., Iturriza-Gomara, M., Vamos, E. E., Green, A., Aanensen, D., Bonsall, D., Buck, D., Macintyre-Cockett, G., de Cesare, M., Pybus, O., Golubchik, T., Scarlett, G., Loveson, K. F., Robson, S. C., Beckett, A., Lindsey, B., Groves, D. C., Parsons, P. J., Mchugh, M. P., Barnes, J. D., Manso, C. F., Grammatopoulos, D., Menger, K. E., Harrison, E., Gunson, R., Peacock, S. J., Gonzalez, G., Carr, M., Mihaela, L., Popovici, O., Brytting, M., Bresner, C., Fuller, W., Workman, T., Mentis, A. F., Kossyvakis, A., Karamitros, T., Pogka, V., Kalliaropoulos, A., Horefti, E., Kontou, A., Martinez-Gonzalez, B., Labropoulou, V., Voulgari-Kokota, A., Evangelidou, M., Bizta, P., Belimezi, M., Lambrechts, L., Doymaz, M. Z., Yazici, M. K., Cetin, N. S., Karaaslan, E., Kallio-Kokko, H., Virtanen, J., Suvanto, M., Nguyen, P. T., Ellonen, P., Hannula, S., Kangas, H., Sreenu, V. B., Burian, K., Terhes, G., Gombos, K., Gyenesei, A., Urban, P., Herczeg, R., Jakab, F., Kemenesi, G., Toth, G. E., Somogyi, B., Zana, B., Zeghbib, S., Kuczmog, A., Foldes, F., Lanszki, Z., Madai, M., Papp, H., Pereszlenyi, C. I., Babinszky, G. C., Dudas, G., Csoma, E., Abou Tayoun, A. N., Alsheikh-Ali, A. A., Loney, T., Nowotny, N., Abdul-Wahab, O., Gonzalez-Candelas, F., Andersen, M. H., Taylor, S., European Centre for Disease Prevention and Control (ECDC), Public Health Wales Microbiology Cardiff, Faculty of Agriculture and Forestry, Department of Agricultural Sciences, and Institute of Biotechnology more...
- Subjects
Infecções Respiratórias ,0301 basic medicine ,MESH: Coronavirus Infections ,Epidemiology ,[SDV]Life Sciences [q-bio] ,Distribution (economics) ,Wastewater ,MESH: Base Sequence ,Severe Acute Respiratory Syndrome ,MESH: World Health Organization ,Pandemic ,MESH: Coronavirus ,MESH: COVID-19 ,Sequencing ,Viral ,Clade ,Nomenclature ,Genome ,biology ,COVID-19 ,Europe ,NGS ,SARS-CoV-2 ,WGS ,nomenclature ,sequencing ,Base Sequence ,Betacoronavirus ,Coronavirus ,Coronavirus Infections ,Genome, Viral ,Humans ,Phylogeography ,Pneumonia, Viral ,RNA, Viral ,RNA-Dependent RNA Polymerase ,Spatio-Temporal Analysis ,World Health Organization ,Pandemics ,C500 ,European region ,3. Good health ,Geography ,MESH: Phylogeography ,MESH: RNA-Dependent RNA Polymerase ,MESH: RNA, Viral ,MESH: Betacoronavirus ,Spatio-Temporal Analysi ,MESH: Genome, Viral ,Cartography ,Human ,Bioquímica ,MESH: Pandemics ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Coronaviru ,030106 microbiology ,03 medical and health sciences ,MESH: Spatio-Temporal Analysis ,MESH: Severe Acute Respiratory Syndrome ,Virology ,MESH: SARS-CoV-2 ,Whole genome sequencing ,MESH: Humans ,Whole Genome Sequencing ,Betacoronaviru ,Coronavirus Infection ,business.industry ,Public Health, Environmental and Occupational Health ,Pneumonia ,biology.organism_classification ,B900 ,030104 developmental biology ,MESH: Pneumonia, Viral ,RNA ,SARS_CoV-2 ,3111 Biomedicine ,MESH: Europe ,Human medicine ,business - Abstract
8 páginas, 3 figuras, We show the distribution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic clades over time and between countries and outline potential genomic surveillance objectives. We applied three genomic nomenclature systems to all sequence data from the World Health Organization European Region available until 10 July 2020. We highlight the importance of real-time sequencing and data dissemination in a pandemic situation, compare the nomenclatures and lay a foundation for future European genomic surveillance of SARS-CoV-2., We gratefully acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiCoV Database used in the phylogenetic analysis. We gratefully acknowledge all the staff working with sample collection, sample preparation, sequencing, data analysis and data sharing in all laboratories in the WHO European Region for making this work possible. more...
- Full Text
- View/download PDF
17. Comparative specificity and sensitivity of ns1-based serological assays for the detection of flavivirus immune response
- Author
-
Alessandro Marcello, Erick Mora-Cárdenas, Chiara Aloise, Tatjana Avšič-Županc, Valentina Faoro, Miša Korva, Nataša Knap Gašper, Pierlanfranco D'Agaro, Ilaria Caracciolo, Mora-Cardenas, E., Aloise, C., Faoro, V., Gasper, N. K., Korva, M., Caracciolo, I., D'Agaro, P., Avsic-zupanc, T., and Marcello, A. more...
- Subjects
RNA viruses ,0301 basic medicine ,Serum Proteins ,Physiology ,viruses ,RC955-962 ,Dengue virus ,Viral Nonstructural Proteins ,medicine.disease_cause ,Antibodies, Viral ,Biochemistry ,Cross-reactivity ,Serology ,Mice ,0302 clinical medicine ,HEK293 Cell ,Immune Physiology ,Arctic medicine. Tropical medicine ,Serologic Test ,Medicine and Health Sciences ,Flavivirus Infections ,Viral ,Enzyme-Linked Immunoassays ,Cloning, Molecular ,Pathology and laboratory medicine ,Inbred BALB C ,Cross Reactivity ,Mice, Inbred BALB C ,Immune System Proteins ,biology ,Viral Vaccine ,virus diseases ,Medical microbiology ,Recombinant Protein ,Recombinant Proteins ,Flavivirus ,Infectious Diseases ,Viruses ,Female ,Pathogens ,Antibody ,Public aspects of medicine ,RA1-1270 ,West Nile virus ,Research Article ,Human ,Gene Expression Regulation, Viral ,Immunology ,030231 tropical medicine ,Enzyme-Linked Immunosorbent Assay ,Research and Analysis Methods ,Microbiology ,Sensitivity and Specificity ,Antibodies ,03 medical and health sciences ,Antigen ,medicine ,Animals ,Humans ,Serologic Tests ,Immunoassays ,Flavivirus Infection ,Flaviviruses ,Animal ,Organisms ,Viral pathogens ,Public Health, Environmental and Occupational Health ,Biology and Life Sciences ,Proteins ,Molecular ,Dengue Virus ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,Virology ,Microbial pathogens ,HEK293 Cells ,Immunoglobulin G ,Immunoglobulin M ,030104 developmental biology ,Gene Expression Regulation ,Immunologic Techniques ,biology.protein ,Cloning - Abstract
Flaviviruses are relevant animal and human pathogens of increasing importance worldwide. The similarities of the initial clinical symptoms and the serological cross-reactivity of viral structural antigens make a laboratory diagnosis of flavivirus infection problematic. The main aim of the present study was the comparative specificity and sensitivity analysis of the non-structural protein NS1 as an antigen to detect flavivirus antibodies in sera from exposed individuals. A strategy for the purification of native recombinant non-structural protein 1 of representative flaviviruses including tick-borne encephalitis, West Nile, Zika and dengue virus was developed. The immunological properties of the purified antigens were analyzed using sera of immunized mice and of infected individuals in comparison with standard commercial assays. Recombinant NS1 protein was confirmed as a valuable option for the detection of flavivirus antibodies with reduced cross-reactivity and high sensitivity offering additional advantages for the detection of vaccine breakthrough cases., Author summary Viruses transmitted by mosquitoes or ticks are on the rise worldwide and may cause life-threatening symptoms, such as brain damage or excessive bleeding. In recent years we experienced several epidemic threats caused by colonization of new geographic areas by the infected vector with large numbers of naive population at risk of infection. Furthermore, increased travel contributed to a rise of imported infections in non-endemic countries. Reliable diagnostics for these viruses have therefore become a pressing need. Serology of infection is complicated by a high level of cross reactivity among structural virion proteins that are generally used as antigens. Therefore, use of the viral non-structural protein NS1 secreted by Flaviviruses, a family of highly significant vector borne viruses that include that infectious cause of Zika, Dengue, west Nile fever and Tick-borne encephalitis, has been proposed as a more specific antigen for detecting specific immune responses. In this work NS1 from representative Flaviviruses were purified from mammalian cells to maintain full antigenic potential and used in serological assays in a comparative analysis with commercial assays. Results showed a high level of specificity and sensitivity of NS1-based assays that can be proposed in a variety of diagnostic formats, from standard assays to multiparametric portable devices for rapid deployment. more...
- Published
- 2020
18. Public health and clinical response to an mpox outbreak in Slovenia: case study, 2022-2023.
- Author
-
Češljarac D, Brečko K, Štrumbelj M, Likar S, Kokošar Ulčar B, Zalaznik M, Kejžar N, Rus KR, Korva M, Avšič Županc T, Grilc E, Murnik Rauh A, Mastnak M, Becner A, Marovt M, Lenart M, and Matičič M
- Abstract
Objectives: The emergence of mpox outbreaks in non-endemic areas, characterised by human-to-human transmission and unique clinical presentations, poses challenges in containment efforts. This study aimed to analyse the 2022 outbreak in Slovenia and characterise the country's response to the outbreak., Methods: A retrospective, observational study analysed all confirmed mpox cases in Slovenia between 1 January 2022 and 31 December 2023 and specific public health measures and responses in the country to contain the mpox outbreak. Data were collected from clinical facilities, public health institutions and civil society organisations and analysed accordingly., Results: Of 149 suspected cases tested, 49 were confirmed, all cisgender men, predominantly men who have sex with men (93%), exhibiting skin lesions, with 20% being HIV infected and 62% reporting recently having sex abroad. Hospitalisation was required in 14%, no specific treatment was needed, and no fatalities occurred. After the rapid spread of mpox from May to mid-July 2022, only occasional cases were detected afterwards until the outbreak's termination in early September. Slovenia's containment strategy started immediately after the first case detection, involving rapid diagnostics and active case search, centralised case management and targeted public health measures. The LGBTIQ+ (Lesbian, Gay, Bisexual, Trans, Intersex, Queer and other sexual identities) community civil society organisation Legebitra played a critical role by launching awareness campaigns and promoting easily accessible vaccination. Despite its late start in September 2022, by the end of 2023, the vaccination campaign achieved coverage of 309 individuals., Conclusions: Slovenia's response to the 2022 mpox outbreak highlights prompt multisectoral collaboration, community engagement and timely public health interventions. Rapid diagnostics, centralised case management and targeted outreach likely contributed to containment. While vaccination had limited impact during the outbreak, its importance for long-term prevention cannot be overstated. As the global threat of mpox persists, continuous surveillance, cross-border cooperation and proactive vaccination strategies are recommended activities to address future challenges., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.) more...
- Published
- 2025
- Full Text
- View/download PDF
19. Metagenomic Sequencing for Diagnosing Listeria-Induced Rhombencephalitis in Patient and Contaminated Cheese Samples: A Case Report.
- Author
-
Resman Rus K, Bosilj M, Triglav T, Jereb M, Zalaznik M, Klešnik M, Češljarac D, Matičič M, Avšič-Županc T, Rus T, and Korva M
- Subjects
- Humans, Adult, Hemolysin Proteins genetics, Heat-Shock Proteins genetics, Bacterial Toxins genetics, Encephalitis diagnosis, Encephalitis microbiology, Male, Rhombencephalon microbiology, Cheese microbiology, Metagenomics methods, Listeria monocytogenes genetics, Listeria monocytogenes isolation & purification, Listeriosis diagnosis, Listeriosis microbiology, High-Throughput Nucleotide Sequencing methods
- Abstract
Among the various causes of rhomboencephalitis, Listeria monocytogenes infection is the most common. However, conventional microbiological methods often yield negative results, making diagnosis challenging and leading to extensive, often inconclusive, diagnostics. Advanced molecular techniques like metagenomic next-generation sequencing (mNGS) offer a powerful and efficient approach to pathogen identification. We present a case of life-threatening rhomboencephalitis in a 32-year-old immunocompetent patient where extensive microbiological, immunological, and biochemical tests were inconclusive. Given the patient's consumption of unpasteurized homemade cheese, neurolisteriosis was suspected, and mNGS was employed on clinical samples (CSF, serum, urine) and the food source to identify the pathogen. mNGS detected L. monocytogenes in both patient samples and the cheese. Mapping reads were distributed across the genome, with 18.9% coverage in clinical samples and 11.8% in the cheese sample. Additionally, the Listeriolysin ( hlyA ) gene was detected with 22.3% coverage in clinical samples and 12.3% in the food source, confirming neurolisteriosis. The patient fully recovered following antibiotic treatment. This case underscores the importance of mNGS in diagnosing CNS infections when conventional methods yield negative results, and supports its inclusion in diagnostic protocols for suspected neurolisteriosis, particularly when traditional methods prove inadequate. more...
- Published
- 2025
- Full Text
- View/download PDF
20. Poor virus-specific T-cell responses early after tick-borne encephalitis virus infection correlate with disease severity.
- Author
-
Aregay A, Slunečko J, Bogovic P, Korva M, Resman Rus K, Knap N, Beicht J, Kubinski M, Saletti G, Steffen I, Strle F, Avšič-Županc T, Osterhaus ADME, and Rimmelzwaan GF
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Severity of Illness Index, Aged, Viral Nonstructural Proteins immunology, Encephalitis, Tick-Borne immunology, Encephalitis, Tick-Borne virology, Encephalitis Viruses, Tick-Borne immunology, T-Lymphocytes immunology, Antibodies, Viral blood, Antibodies, Viral immunology
- Abstract
Tick-borne encephalitis virus (TBEV) infection may cause acute central nervous system inflammation varying in clinical manifestations and severity. A possible correlation of TBEV-specific antibody and cell-mediated immune responses, shortly after infection, with clinical manifestations, severity and long-term outcome has been poorly investigated. In a cohort of thirty early tick-borne encephalitis (TBE) patients, we assessed the magnitude, specificity and functional properties of TBEV-specific T-cell and antibody responses. These responses early during disease were assessed in view of clinical manifestations, severity and long-term outcome. TBEV-specific T-cell responses to C, E, NS1, and NS5 proteins were significantly lower in patients with severe acute illness than in patients with mild TBE. Lower T-cell responses to E, NS1, and NS5 proteins also correlated with the development of meningoencephalomyelitis. Virus-specific antibody titres early after infection did not correlate with disease severity, clinical manifestations, or long-term outcome in this study, possibly due to the small number of patients of which matching serum and peripheral blood mononuclear cells were available. The findings suggest that virus-specific T cells afford a certain degree of protection against the development of severe TBEV-induced disease. more...
- Published
- 2024
- Full Text
- View/download PDF
21. MetaAll: integrative bioinformatics workflow for analysing clinical metagenomic data.
- Author
-
Bosilj M, Suljič A, Zakotnik S, Slunečko J, Kogoj R, and Korva M
- Subjects
- Humans, COVID-19 virology, COVID-19 diagnosis, SARS-CoV-2 genetics, Metagenome, Software, Metagenomics methods, Computational Biology methods, Workflow
- Abstract
Over the past decade, there have been many improvements in the field of metagenomics, including sequencing technologies, advances in bioinformatics and the development of reference databases, but a one-size-fits-all sequencing and bioinformatics pipeline does not yet seem achievable. In this study, we address the bioinformatics part of the analysis by combining three methods into a three-step workflow that increases the sensitivity and specificity of clinical metagenomics and improves pathogen detection. The individual tools are combined into a user-friendly workflow suitable for analysing short paired-end (PE) and long reads from metagenomics datasets-MetaAll. To demonstrate the applicability of the developed workflow, four complicated clinical cases with different disease presentations and multiple samples collected from different biological sites as well as the CAMI Clinical pathogen detection challenge dataset were used. MetaAll was able to identify putative pathogens in all but one case. In this case, however, traditional microbiological diagnostics were also unsuccessful. In addition, co-infection with Haemophilus influenzae and Human rhinovirus C54 was detected in case 1 and co-infection with SARS-Cov-2 and Influenza A virus (FluA) subtype H3N2 was detected in case 3. In case 2, in which conventional diagnostics could not find a pathogen, mNGS pointed to Klebsiella pneumoniae as the suspected pathogen. Finally, this study demonstrated the importance of combining read classification, contig validation and targeted reference mapping for more reliable detection of infectious agents in clinical metagenome samples., (© The Author(s) 2024. Published by Oxford University Press.) more...
- Published
- 2024
- Full Text
- View/download PDF
22. Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins.
- Author
-
Aregay A, Slunečko J, Korva M, Bogovic P, Resman Rus K, Knap N, Beicht J, Kubinski M, Saletti G, Avšič-Županc T, Steffen I, Strle F, Osterhaus ADME, and Rimmelzwaan GF
- Abstract
Tick-borne encephalitis virus (TBEV) vaccine breakthrough (VBT) infections are not uncommon in endemic areas. The clinical and immunological outcomes have been poorly investigated. We assessed the magnitude and specificity of virus-specific antibody and T cell responses after TBE in previously vaccinated subjects and compared the results with those of unvaccinated TBE patients and study subjects that received vaccination without VBT infection. Symptomatic TBEV infection of unvaccinated study subjects induced virus-specific antibody responses to the E protein and non-structural protein 1 (NS1) as well as T cell responses to structural and other non-structural (NS) proteins. After VBT infections, significantly impaired NS1-specific antibody responses were observed, while the virus-specific T cell responses to the NS proteins were relatively strong. VBT infection caused predominantly moderate to severe disease during hospitalization. The level of TBEV EDIII- and NS1-specific antibodies in unvaccinated convalescent patients inversely correlated with TBE severity and neurological symptoms early after infection., (© 2024. The Author(s).) more...
- Published
- 2024
- Full Text
- View/download PDF
23. Serological response after COVID-19 infection compared to vaccination against COVID-19 in children with autoimmune rheumatic diseases.
- Author
-
Šinkovec Savšek T, Zajc Avramovič M, Avčin T, Korva M, Avšič-Županc T, and Toplak N
- Subjects
- Humans, Male, Child, Female, Adolescent, Immunoglobulin G blood, Vaccination methods, COVID-19 Vaccines immunology, COVID-19 Vaccines adverse effects, COVID-19 Vaccines administration & dosage, Immunoglobulin A blood, Immunoglobulin A immunology, COVID-19 prevention & control, COVID-19 immunology, Rheumatic Diseases immunology, Rheumatic Diseases drug therapy, BNT162 Vaccine immunology, Autoimmune Diseases immunology, Antibodies, Viral blood, SARS-CoV-2 immunology
- Abstract
Background: Paediatric patients with autoimmune rheumatic diseases (pARD) have a dysregulated immune system, so infections present a major threat to them. To prevent severe COVID-19 infections we aimed to vaccinate them as soon as possible. Studies have shown that the BNT162b2 vaccine is safe, effective, and immunogenic, however, in a short observation period, only., Methods: The main objective was to compare the serological response between three groups of pARD: after SARS-CoV-2 infection, after vaccination against COVID-19 with two doses of the BNT162b2 vaccine, and after experiencing both events. Data on demographics, diagnosis, therapy, and serology (anti-SARS-CoV-2 IgG/IgA) were collected from March 2020 to April 2022. For statistical analysis ANOVA, Mann-Whitney U test, Chi-square test and Fisher's exact test were applied. To compare adverse events (AE) after vaccination we included a control group of healthy adolescents., Results: We collected data from 115 pARD; from 92 after infection and 47 after vaccination. Twenty-four were included in both groups. Serological data were available for 47 pARD after infection, 25 after vaccination, and 21 after both events. Serological response was better after vaccination and after both events compared to after infection only. No effect of medication on the antibody levels was noted. The safety profile of the vaccine was good. Systemic AE after the first dose of the vaccine were more common in healthy adolescents compared to pARD. In the observation period of 41.3 weeks, 60% of vaccinated pARD did not experience a symptomatic COVID-19 infection., Conclusions: IgG and IgA anti-SARS-CoV-2 levels were higher after vaccination and after both events compared to after infection only. Six months after vaccination we observed an increase in antibody levels, suggesting that pARD had been exposed to SARS-CoV-2 but remained asymptomatic., Trial Registration: The study was approved by the Medical Ethics Committee of the Republic of Slovenia (document number: 0120-485/2021/6)., (© 2024. The Author(s).) more...
- Published
- 2024
- Full Text
- View/download PDF
24. Influenza A, Influenza B, human respiratory syncytial virus and SARSCoV-2 molecular diagnostics and epidemiology in the post COVID-19 era.
- Author
-
Luštrek M, Cesar Z, Suljič A, Kogoj R, Knap N, Virant MJ, Uršič T, Petrovec M, Avšič-Županc T, and Korva M
- Subjects
- Humans, Male, Female, Coinfection epidemiology, Coinfection diagnosis, Middle Aged, Adult, Molecular Diagnostic Techniques methods, Seasons, Aged, COVID-19 epidemiology, COVID-19 diagnosis, Influenza B virus isolation & purification, Influenza B virus genetics, Influenza, Human epidemiology, Influenza, Human diagnosis, Influenza, Human virology, SARS-CoV-2 genetics, SARS-CoV-2 isolation & purification, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections diagnosis, Respiratory Syncytial Virus, Human isolation & purification, Respiratory Syncytial Virus, Human genetics, Influenza A virus isolation & purification, Influenza A virus genetics
- Abstract
Background: The concurrent circulation of SARS-CoV-2 with other respiratory viruses is unstoppable and represents a new diagnostic reality for clinicians and clinical microbiology laboratories. Multiplexed molecular testing on automated platforms that focus on the simultaneous detection of multiple respiratory viruses in a single tube is a useful approach for current and future diagnosis of respiratory infections in the clinical setting., Methods: Two time periods were included in the study: from February to April 2022, an early 2022 period, during the gradual lifting of COVID-19 prevention measures in the country, and from October 2022 to April 2023, the 2022/23 respiratory infections season. We analysed a total of 1,918 samples in the first period and 18,131 respiratory samples in the second period using a multiplex molecular assay for the simultaneous detection of Influenza A (Flu-A), Influenza B (Flu-B), Human Respiratory Syncytial Virus (HRSV) and SARS-CoV-2., Results: The results from early 2022 showed a strong dominance of SARS-CoV-2 infections with 1,267/1,918 (66.1%) cases. Flu-A was detected in 30/1,918 (1.6%) samples, HRSV in 14/1,918 (0.7%) samples, and Flu-B in 2/1,918 (0.1%) samples. Flu-A/SARS-CoV-2 co-detections were observed in 11/1,267 (0.9%) samples, and HRSV/SARS-CoV-2 co-detection in 5/1,267 (0.4%) samples. During the 2022/23 winter respiratory season, SARS-CoV-2 was detected in 1,738/18,131 (9.6%), Flu-A in 628/18,131 (3.5%), Flu-B in 106/18,131 (0.6%), and HRSV in 505/18,131 (2.8%) samples. Interestingly, co-detections were present to a similar extent as in early 2022., Conclusion: The results show that the multiplex molecular approach is a valuable tool for the simultaneous laboratory diagnosis of SARS-CoV-2, Flu-A/B, and HRSV in hospitalized and outpatients. Infections with Flu-A/B, and HRSV occurred shortly after the COVID-19 control measures were lifted, so a strong reoccurrence of various respiratory infections and co-detections in the post COVID-19 period was to be expected., (© 2024. The Author(s).) more...
- Published
- 2024
- Full Text
- View/download PDF
25. Elevated levels of serum muscle enzymes in the initial phase of tick-borne encephalitis.
- Author
-
Bogovič P, Lotrič-Furlan S, Ogrinc K, Avšič Županc T, Korva M, Kastrin A, Trampuš Bakija A, Strle K, and Strle F
- Abstract
Purpose: Since some patients with tick-borne encephalitis (TBE) have pronounced myalgias, and since myositis is reported in Flavivirus diseases such as dengue, we performed systematic search for abnormalities of muscle enzymes in a group of patients in whom the presence of tick-borne encephalitis virus (TBEV) RNA in the first phase of the disease was demonstrated and who developed second phase of TBE., Methods: Total leukocyte and platelet blood counts were determined routinely at the initial examination during the first and the second phase of TBE. Activity of aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK), myoglobin and troponin was determined from the available stored serum specimens; the first and second phase disease specimens were tested simultaneously., Results: Of 24 patients with biphasic course of TBE, 83% had leukopenia, 65% thrombocytopenia, 83% elevated AST and 4% elevated ALT level. Furthermore, 33% had elevated serum CK, 26% myoglobin and 22% troponin activity; at least one of the muscle enzymes was elevated in 42% of patients. Leukopenia, thrombocytopenia, elevated liver enzymes and elevations of CK and myoglobin were present in the initial phase but resolve later, while troponin abnormalities were also found in the second phase of TBE., Conclusions: The present study exposes that in addition to previously known leukopenia, thrombocytopenia and increased liver enzymes activity, the initial phase of TBE is relatively often associated also with elevated muscle enzymes. Clinical relevance of these findings remains to be determined. more...
- Published
- 2024
- Full Text
- View/download PDF
26. Efficient SARS-CoV-2 variant detection and monitoring with Spike Screen next-generation sequencing.
- Author
-
Suljič A, Zorec TM, Zakotnik S, Vlaj D, Kogoj R, Knap N, Petrovec M, Poljak M, Avšič-Županc T, and Korva M
- Subjects
- Humans, Mutation, Genome, Viral, Slovenia epidemiology, SARS-CoV-2 genetics, SARS-CoV-2 isolation & purification, High-Throughput Nucleotide Sequencing methods, COVID-19 virology, COVID-19 diagnosis, COVID-19 epidemiology, Spike Glycoprotein, Coronavirus genetics
- Abstract
The emergence and rapid spread of SARS-CoV-2 prompted the global community to identify innovative approaches to diagnose infection and sequence the viral genome because at several points in the pandemic positive case numbers exceeded the laboratory capacity to characterize sufficient samples to adequately respond to the spread of emerging variants. From week 10, 2020, to week 13, 2023, Slovenian routine complete genome sequencing (CGS) surveillance network yielded 41 537 complete genomes and revealed a typical molecular epidemiology with early lineages gradually being replaced by Alpha, Delta, and finally Omicron. We developed a targeted next-generation sequencing based variant surveillance strategy dubbed Spike Screen through sample pooling and selective SARS-CoV-2 spike gene amplification in conjunction with CGS of individual cases to increase throughput and cost-effectiveness. Spike Screen identifies variant of concern (VOC) and variant of interest (VOI) signature mutations, analyses their frequencies in sample pools, and calculates the number of VOCs/VOIs at the population level. The strategy was successfully applied for detection of specific VOC/VOI mutations prior to their confirmation by CGS. Spike Screen complemented CGS efforts with an additional 22 897 samples sequenced in two time periods: between week 42, 2020, and week 24, 2021, and between week 37, 2021, and week 2, 2022. The results showed that Spike Screen can be applied to monitor VOC/VOI mutations among large volumes of samples in settings with limited sequencing capacity through reliable and rapid detection of novel variants at the population level and can serve as a basis for public health policy planning., (© The Author(s) 2024. Published by Oxford University Press.) more...
- Published
- 2024
- Full Text
- View/download PDF
27. Sequencing analysis of SARS-CoV-2 cases in Slovenian long-term care facilities to support outbreak control.
- Author
-
Kogoj R, Grašek M, Suljič A, Zakotnik S, Vlaj D, Kotnik Koman K, Fafangel M, Petrovec M, Avšič-Županc T, and Korva M
- Subjects
- Humans, Slovenia epidemiology, Aged, Female, Male, Disease Outbreaks, Aged, 80 and over, High-Throughput Nucleotide Sequencing, Phylogeny, Middle Aged, COVID-19 epidemiology, COVID-19 transmission, COVID-19 prevention & control, SARS-CoV-2 genetics, Long-Term Care statistics & numerical data
- Abstract
Introduction: Residents of long-term care facilities (LTCFs) are at high risk of morbidity and mortality due to COVID-19, especially when new variants of concern (VOC) emerge. To provide intradisciplinary data in order to tailor public health interventions during future epidemics, available epidemiologic and genomic data from Slovenian LTCFs during the initial phases of the COVID-19 pandemic was analyzed., Methods: The first part of the study included SARS-CoV-2 reverse-transcription Real-Time PCR (rtRT-PCR) positive LTCF residents, from 21 facilities with COVID-19 outbreaks occurring in October 2020. The second part of the study included SARS-CoV-2 rtRT-PCR positive LTCF residents and staff between January and April 2021, when VOC Alpha emerged in Slovenia. Next-generation sequencing (NGS) was used to acquire SARS-CoV-2 genomes, and lineage determination. In-depth phylogenetic and mutational profile analysis were performed and coupled with available field epidemiological data to assess the dynamics of SARS-CoV-2 introduction and transmission., Results: 370/498 SARS-CoV-2 positive residents as well as 558/699 SARS-CoV-2 positive residents and 301/358 staff were successfully sequenced in the first and second part of the study, respectively. In October 2020, COVID-19 outbreaks in the 21 LTCFs were caused by intra-facility transmission as well as multiple independent SARS-CoV-2 introductions. The Alpha variant was confirmed in the first LTCF resident approximately 1.5 months after the first Alpha case was identified in Slovenia. The data also showed a slower replacement of existing variants by Alpha in residents compared to staff and the general population., Discussion: Multiple SARS CoV-2 introductions as well as intra-facility spreading impacted disease transmission in Slovenian LTCFs. Timely implementation of control measures aimed at limiting new introductions while controlling in-facility transmission are of paramount importance, especially as new VOCs emerge. Sequencing, in conjunction with epidemiological data, can facilitate the determination of the need for future improvements in control measures to protect LTCF residents from COVID-19 or other respiratory infections., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Kogoj, Grašek, Suljič, Zakotnik, Vlaj, Kotnik Koman, Fafangel, Petrovec, Avšič-Županc and Korva.) more...
- Published
- 2024
- Full Text
- View/download PDF
28. Enrichment of SARS-CoV-2 sequence from nasopharyngeal swabs whilst identifying the nasal microbiome.
- Author
-
Alrezaihi A, Penrice-Randal R, Dong X, Prince T, Randle N, Semple MG, Openshaw PJM, MacGill T, Myers T, Orr R, Zakotnik S, Suljič A, Avšič-Županc T, Petrovec M, Korva M, AlJabr W, and Hiscox JA
- Subjects
- Humans, SARS-CoV-2 genetics, Genome, Viral, Nasopharynx, COVID-19 diagnosis, Microbiota genetics
- Abstract
Simultaneously characterising the genomic information of coronaviruses and the underlying nasal microbiome from a single clinical sample would help characterise infection and disease. Metatranscriptomic approaches can be used to sequence SARS-CoV-2 (and other coronaviruses) and identify mRNAs associated with active transcription in the nasal microbiome. However, given the large sequence background, unenriched metatranscriptomic approaches often do not sequence SARS-CoV-2 to sufficient read and coverage depth to obtain a consensus genome, especially with moderate and low viral loads from clinical samples. In this study, various enrichment methods were assessed to detect SARS-CoV-2, identify lineages and define the nasal microbiome. The methods were underpinned by Oxford Nanopore long-read sequencing and variations of sequence independent single primer amplification (SISPA). The utility of the method(s) was also validated on samples from patients infected seasonal coronaviruses. The feasibility of profiling the nasal microbiome using these enrichment methods was explored. The findings shed light on the performance of different enrichment strategies and their applicability in characterising the composition of the nasal microbiome., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier B.V.) more...
- Published
- 2024
- Full Text
- View/download PDF
29. Herpesviridae and Atypical Bacteria Co-Detections in Lower Respiratory Tract Samples of SARS-CoV-2-Positive Patients Admitted to an Intensive Care Unit.
- Author
-
Grubelnik G, Korva M, Kogoj R, Polanc T, Mavrič M, Jevšnik Virant M, Uršič T, Keše D, Seme K, Petrovec M, Jereb M, and Avšič-Županc T
- Abstract
Shortly after the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), cases of viral, bacterial, and fungal coinfections in hospitalized patients became evident. This retrospective study investigates the prevalence of multiple pathogen co-detections in 1472 lower respiratory tract (LRT) samples from 229 SARS-CoV-2-positive patients treated in the largest intensive care unit (ICU) in Slovenia. In addition to SARS-CoV-2, (rt)RT-PCR tests were used to detect cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella zoster virus (VZV), and atypical bacteria: Chlamydia pneumoniae , Mycoplasma pneumoniae and Legionella pneumophila/ spp. At least one co-detection was observed in 89.1% of patients. EBV, HSV-1, and CMV were the most common, with 74.7%, 58.1%, and 38.0% of positive patients, respectively. The median detection time of EBV, HSV-1, and CMV after initial SARS-CoV-2 confirmation was 11 to 20 days. Bronchoalveolar lavage (BAL) and tracheal aspirate (TA) samples showed equivalent performance for the detection of EBV, CMV, and HSV-1 in patients with both available samples. Our results indicate that SARS-CoV-2 infection could be a risk factor for latent herpesvirus reactivation, especially HSV-1, EBV, and CMV. However, additional studies are needed to elucidate the clinical importance of these findings. more...
- Published
- 2024
- Full Text
- View/download PDF
30. Review of virological methods for laboratory diagnosis and characterization of monkeypox virus (MPXV): lessons learned from the 2022 Mpox outbreak.
- Author
-
Resman Rus K, Zakotnik S, Sagadin M, Kolenc M, Skubic L, Knap N, Korva M, Poljak M, and Avšič-Županc T
- Subjects
- Humans, Clinical Laboratory Techniques, Disease Outbreaks prevention & control, Monkeypox virus genetics, Mpox, Monkeypox diagnosis, Mpox, Monkeypox epidemiology
- Abstract
Monkeypox virus (MPXV), originally endemic in West Africa (Clade II) and Central Africa (Clade I), has recently emerged worldwide and has reinforced the need for rapid and accurate MPXV diagnostics. This review presents and critically discusses the range of virological methods for laboratory diagnosis and characterization of MPXV as well as related lessons learned and practical experience gained from the 2022 Mpox global outbreak. Real-time PCR is currently considered the diagnostic gold standard and ensures accurate and timely confirmation of suspected Mpox cases based on suspicious skin lesions, and digital PCR improves the precision of MPXV DNA quantification. Whole genome sequencing reveals the diversity within the Clade IIb outbreak and highlights the role of microevolution in the adaptation of the virus to the human host. Continuous genomic surveillance is important for better understanding of human-to-human transmission and prevention of the emergence of variola virus-like strains. Traditional virological methods such as electron microscopy and virus isolation remain essential for comprehensive virus characterization, particularly in the context of vaccine and antiviral drug development. Despite the current challenges, serological tests detecting a range of anti-MPXV antibodies are important adjunct diagnostic and research tools for confirmation of late-presenting or asymptomatic MPXV cases, contact tracing, epidemiological studies, seroepidemiological surveys, and better understanding of the role of IgG and neutralizing antibodies in the immune response to infection and vaccination. A multidisciplinary approach combining advanced molecular techniques with traditional virological methods is important for rapid and reliable diagnosis, surveillance, and control of the outbreak. more...
- Published
- 2024
31. Comparing COVID-19 severity in patients hospitalized for community-associated Delta, BA.1 and BA.4/5 variant infection.
- Author
-
Sočan M, Mrzel M, Prosenc K, Korva M, Avšič-Županc T, Poljak M, Lunar MM, and Zupanič T
- Subjects
- Adolescent, Child, Aged, 80 and over, Humans, Female, COVID-19 Vaccines, SARS-CoV-2, Critical Care, Databases, Factual, COVID-19 epidemiology
- Abstract
Background: Despite decreasing COVID-19 disease severity during the Omicron waves, a proportion of patients still require hospitalization and intensive care., Objective: To compare demographic characteristics, comorbidities, vaccination status, and previous infections in patients hospitalized for community-associated COVID-19 (CAC) in predominantly Delta, Omicron BA.1 and BA.4/5 SARS-CoV-2 waves., Methods: Data were extracted from three national databases-the National COVID-19 Database, National Vaccination Registry and National Registry of Hospitalizations., Results: Among the hospitalized CAC patients analyzed in this study, 5,512 were infected with Delta, 1,120 with Omicron BA.1, and 1,143 with the Omicron BA.4/5 variant. The age and sex structure changed from Delta to BA.4/5, with the proportion of women (9.5% increase), children and adolescents (10.4% increase), and octa- and nonagenarians increasing significantly (24.5% increase). Significantly more patients had comorbidities (measured by the Charlson Comorbidity Index), 30.3% in Delta and 43% in BA.4/5 period. The need for non-invasive ventilatory support (NiVS), ICU admission, mechanical ventilation (MV), and in-hospital mortality (IHM) decreased from Delta to Omicron BA.4/5 period for 12.6, 13.5, 11.5, and 6.3%, respectively. Multivariate analysis revealed significantly lower odds for ICU admission (OR 0.68, CI 0.54-0.84, p < 0.001) and IHM (OR 0.74, CI 0.58-0.93, p = 0.011) during the Delta period in patients who had been fully vaccinated or boosted with a COVID-19 vaccine within the previous 6 months. In the BA.1 variant period, patients who had less than 6 months elapsed between the last vaccine dose and SARS-CoV-2 positivity had lower odds for MV (OR 0.38, CI 0.18-0.72, p = 0.005) and IHM (OR 0.56, CI 0.37- 0.83, p = 0.005), but not for NIVS or ICU admission., Conclusion: The likelihood of developing severe CAC in hospitalized patients was higher in those with the Delta and Omicron BA.1 variant compared to BA.4/5., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Sočan, Mrzel, Prosenc, Korva, Avšič-Županc, Poljak, Lunar and Zupanič.) more...
- Published
- 2024
- Full Text
- View/download PDF
32. Hantavirus Pulmonary Syndrome Caused by Puumala Orthohantavirus-A Case Report and Literature Review.
- Author
-
Santini M, Ljubić J, Šoštar N, Vilibić-Čavlek T, Bogdanić M, Zakotnik S, Avšič-Županc T, Korva M, Kurolt IC, Radmanić L, Šimičić P, Krznarić J, Gjurašin B, Kutleša M, Višković K, Balent NC, Žunec R, Margeta Marić I, Ribarović A, and Židovec-Lepej S more...
- Abstract
In this article, we report on a rare case of acute respiratory distress syndrome (ARDS) caused by the Puumala orthohantavirus (PUUV), which is typically associated with hemorrhagic fever with renal syndrome (HFRS). This is the first documented case of PUUV-associated ARDS in Southeast Europe. The diagnosis was confirmed by serum RT-PCR and serology and corroborated by phylogenetic analysis and chemokine profiling. The patient was a 23-year-old male from Zagreb, Croatia, who had recently traveled throughout Europe. He presented with fever, headache, abdominal pain, and sudden onset of ARDS. Treatment involved high-flow nasal cannula oxygen therapy and glucocorticoids, which resulted in a full recovery. A systematic literature review identified 10 cases of hantavirus pulmonary syndrome (HPS) caused by PUUV in various European countries and Turkey between 2002 and 2023. The median age of patients was 53 years (range 24-73), and six of the patients were male. Most patients were treated in intensive care units, but none received antiviral therapy targeting PUUV. Eight patients survived hospitalization. The presented case highlights the importance of considering HPS in the differential diagnosis of ARDS, even in areas where HFRS is the dominant form of hantavirus infection. more...
- Published
- 2023
- Full Text
- View/download PDF
33. Evidence of tick-borne encephalitis virus neutralizing antibodies in Serbian individuals exposed to tick bites.
- Author
-
Banović P, Mijatović D, Bogdan I, Simin V, Meletis E, Kostoulas P, Resman Rus K, Knap N, Korva M, Avšič-Županc T, and Cabezas-Cruz A
- Abstract
Introduction: Tick-borne encephalitis (TBE) is an emerging vector-borne and food-borne disease caused by the tick-borne encephalitis virus (TBEV; Orthoflavivirus encephalitidis ), with a distribution spanning the Eurasian continent. Despite its significant public health impact in various European regions, TBE remains largely underdiagnosed in Serbia due to limited awareness and diagnostic challenges. In response to this, our study aimed to comprehensively assess TBEV exposure in individuals infested with ticks and to identify potential TBEV foci within Serbia., Materials and Methods: From 2019 to 2021, we conducted an observational study involving 450 patients who reported tick infestations., Results: Our demographic analysis revealed a median age of 38 years, with a slight male predominance among the participants. We documented tick infestations in 38 municipalities across 14 districts of Serbia, with a notable concentration in proximity to Fruška Gora Mountain. The ticks most frequently removed were Ixodes ricinus , with nymphs and adult females being the predominant stages. On average, nymphs were removed after about 27.1 hours of feeding, while adult females remained attached for approximately 44.4 hours. Notably, we found age as a significant predictor of infestation time for both nymphs and adult females. Furthermore, we detected TBEV-neutralizing antibodies in 0.66% of the serum samples, shedding light on potential TBEV foci, particularly in Fruška Gora Mountain and other regions of Serbia., Conclusion: Our study emphasizes the urgent need for active TBE surveillance programs, especially in areas suspected of hosting TBEV foci, in order to assess the true TBE burden, identify at-risk populations, and implement effective preventive measures., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2023 Banović, Mijatović, Bogdan, Simin, Meletis, Kostoulas, Resman Rus, Knap, Korva, Avšič-Županc and Cabezas-Cruz.) more...
- Published
- 2023
- Full Text
- View/download PDF
34. External quality assessment of orthohantavirus and lymphocytic choriomeningitis virus molecular detection and serology in Europe, 2021.
- Author
-
Erdin M, Stanoeva KR, Mögling R, Korva M, Knap N, Resman Rus K, Domingo C, Reimerink JH, de Vries A, Alburkat H, Utriainen M, Gossner CM, Sironen T, Avšič-Županc T, Reusken CB, and Vapalahti O
- Subjects
- Humans, Lymphocytic choriomeningitis virus genetics, Europe epidemiology, Antibodies, Viral, Orthohantavirus, Hantavirus Infections diagnosis
- Abstract
BackgroundRodent-borne viruses such as orthohantaviruses and arenaviruses cause considerable disease burden with regional and temporal differences in incidence and clinical awareness. Therefore, it is important to regularly evaluate laboratory diagnostic capabilities, e.g. by external quality assessments (EQA).AimWe wished to evaluate the performance and diagnostic capability of European expert laboratories to detect orthohantaviruses and lymphocytic choriomeningitis virus (LCMV) and human antibody response towards orthohantaviruses.MethodsWe conducted an EQA in 2021; molecular panels consisted of 12 samples, including different orthohantaviruses (Seoul, Dobrava-Belgrade (DOBV), Puumala (PUUV) and Hantaan orthohantavirus), LCMV and negative controls. Serological panels consisted of six human serum samples reactive to PUUV, DOBV or negative to orthohantaviruses. The EQA was sent to 25 laboratories in 20 countries.ResultsThe accuracy of molecular detection of orthohantaviruses varied (50‒67%, average 62%) among 16 participating laboratories, while LCMV samples were successfully detected in all 11 participating laboratories (91-100%, average 96%). The accuracy of serological diagnosis of acute and past orthohantavirus infections was on average 95% among 20 participating laboratories and 82% in 19 laboratories, respectively. A variety of methods was used, with predominance of in-house assays for molecular tests, and commercial assays for serological ones.ConclusionSerology, the most common tool to diagnose acute orthohantavirus infections, had a high accuracy in this EQA. The molecular detection of orthohantaviruses needs improvement while LCMV detection (performed in fewer laboratories) had 95% accuracy. Further EQAs are recommended to be performed periodically to monitor improvements and challenges in the diagnostics of rodent-borne diseases. more...
- Published
- 2023
- Full Text
- View/download PDF
35. Molecular epidemiology of the 2022 monkeypox virus outbreak in Slovenia.
- Author
-
Resman Rus K, Zakotnik S, Sagadin M, Knap N, Suljič A, Zorec TM, Mastnak M, Petrovec M, Poljak M, Korva M, and Avšič-Županc T
- Subjects
- Male, Humans, Molecular Epidemiology, Slovenia epidemiology, Phylogeny, Disease Outbreaks, Monkeypox virus genetics, Mpox, Monkeypox diagnosis, Mpox, Monkeypox epidemiology
- Abstract
Introduction: Monkeypox virus (MPXV), typically endemic in West and Central Africa, has raised global concern due to the recent outbreak in several non-endemic countries with human-to-human transmission. Here we present a comprehensive analysis of MPXV genomes from Slovenia., Methods: Two real-time polymerase chain reaction (RT-PCR) assays for Orthopoxvirus (OPV) and MPXV genes were used for laboratory confirmation of mpox. Complete MPXV genomic sequences were obtained using nanopore long reads and Illumina technology. Phylogenetic analyses compared the Slovenian MPXV sequences with the global sequences., Results: A total of 49 laboratory-confirmed mpox cases were diagnosed in Slovenia in 2022, mainly affecting males under 40. In 48 cases, a complete genome sequence was obtained and phylogenetic analysis revealed five distinct lineages (B.1, B.1.14, B.1.2, B.1.3, and A.2.1), with B.1 and B.1.3 dominating, suggesting multiple introductions into Slovenia. Genome analysis revealed significant divergence from the reference MPXV-M5312_HM12_Rivers., Conclusions: The genetic diversity observed in the Slovenian MPXV sequences sheds light on the complex dynamics of the 2022 mpox outbreak and highlights the need for further research to understand the impact of mutations on MPXV functional characteristics and their role in the evolution and diversification of current lineages. more...
- Published
- 2023
36. Association of Persistent Symptoms after Lyme Neuroborreliosis and Increased Levels of Interferon-α in Blood.
- Author
-
Hernández SA, Ogrinc K, Korva M, Kastrin A, Bogovič P, Rojko T, Kelley KW, Weis JJ, Strle F, and Strle K
- Subjects
- Humans, Interferon-alpha therapeutic use, Cytokines, Immunologic Factors, Anti-Bacterial Agents therapeutic use, Lyme Neuroborreliosis drug therapy, Lyme Neuroborreliosis diagnosis
- Abstract
Patients who have Lyme neuroborreliosis (LNB) might experience lingering symptoms that persist despite antibiotic drug therapy. We tested whether those symptoms are caused by maladaptive immune responses by measuring 20 immune mediators in serum and cerebrospinal fluid (CSF) in 79 LNB patients followed for 1 year. At study entry, most mediators were highly concentrated in CSF, the site of the infection. Those responses resolved with antibiotic therapy, and associations between CSF cytokines and signs and symptoms of LNB were no longer observed. In contrast, subjective symptoms that persisted after use of antibiotics were associated with increased levels of serum interferon-α (IFN-α), which were already observed at study entry, and remained increased at each subsequent timepoint. Highest IFN-α levels corresponded with severe disease. Although the infection serves as the initial trigger, sequelae after antibiotic therapy are associated with unremitting systemic IFN-α levels, consistent with the pathogenic role of this cytokine in interferonopathies in other conditions. more...
- Published
- 2023
- Full Text
- View/download PDF
37. Disease relapse rate in children with autoimmune rheumatic diseases after COVID-19 infection and vaccination.
- Author
-
Šinkovec Savšek T, Zajc Avramovič M, Avčin T, Korva M, Avšič Županc T, and Toplak N
- Subjects
- Humans, Child, BNT162 Vaccine, Pandemics, SARS-CoV-2, Vaccination, Chronic Disease, COVID-19 epidemiology, COVID-19 prevention & control, Autoimmune Diseases epidemiology, Rheumatic Diseases epidemiology
- Abstract
Background: Paediatric patients with autoimmune rheumatic diseases (pARD) are often immunocompromised because of the disease and/or the therapy they receive. At the beginning of COVID-19 pandemic there was a great concern about the possibility of severe SARS-CoV-2 infection in these patients. The best method of protection is vaccination, so as soon as vaccine was licenced, we aimed to vaccinate them. Data on disease relapse rate after COVID-19 infection and vaccination are scarce, but they play important role in everyday clinical decisions., Methods: The aim of this study was to determine the relapse rate of autoimmune rheumatic disease (ARD) after COVID-19 infection and vaccination. Data on demographic, diagnosis, disease activity, therapy, clinical presentation of the infection and serology were collected from pARD who had COVID-19 and from pARD who were vaccinated against COVID-19, from March 2020 to April 2022. All vaccinated patients received two doses of the BNT162b2 BioNTech vaccine, on average, 3.7 (S.D.=1.4) weeks apart. Activity of the ARD was followed prospectively. Relapse was defined as a worsening of the ARD in a time frame of 8 weeks after infection or vaccination. For statistical analysis, Fisher's exact test and Mann-Whitney U test were used., Results: We collected data from 115 pARD, which we divided into two groups. We included 92 pARD after infection and 47 after vaccination, with 24 in both groups (they were infected before/after vaccination). In 92 pARD we registered 103 SARS-CoV-2 infections. Infection was asymptomatic in 14%, mild in 67% and moderate in 18%, 1% required hospitalization; 10% had a relapse of ARD after infection and 6% after vaccination. There was a trend towards higher disease relapse rate after infection compared to vaccination, but the difference was not statistically significant (p = 0.76). No statistically significant difference was detected in the relapse rate depending on the clinical presentation of the infection (p = 0.25) or the severity of the clinical presentation of COVID-19 between vaccinated and unvaccinated pARD (p = 0.31)., Conclusions: There is a trend towards a higher relapse rate in pARD after infection compared to vaccination and connection between the severity of COVID-19 and vaccination status is plausible. Our results were, however, not statistically significant., (© 2023. The Author(s).) more...
- Published
- 2023
- Full Text
- View/download PDF
38. Dendritic cell activation and cytokine response in vaccine breakthrough TBE patients after in vitro stimulation with TBEV.
- Author
-
Marušić M, Kopitar AN, Korva M, Knap N, Bogovič P, Strle F, Ihan A, and Avšič-Županc T
- Subjects
- Humans, Cytokines, Leukocytes, Mononuclear, Interleukin-12, Dendritic Cells, Encephalitis, Tick-Borne, Viral Vaccines
- Abstract
Tick-borne encephalitis (TBE) is a viral infection of the human central nervous system caused by the TBE virus (TBEV). The most effective protective measure against TBE is vaccination. Despite the highly immunogenic vaccine, cases of vaccine breakthroughs (VBTs) occur. One of the first targets of infection is dendritic cells (DC), which represent a fundamental bridge between innate and adaptive immunity through antigen presentation, costimulation, and cytokine production. Therefore, we investigated the activation and maturation of DCs and cytokine production after in vitro TBEV stimulation of peripheral blood mononuclear cells (PBMCs) obtained from VBT and unvaccinated TBE patients. Our results showed that the expression of HLA-DR and CD86 on DCs, was upregulated to a similar extent in both vaccinated and unvaccinated TBE patients but differed in cytokine production after stimulation with TBEV. PBMCs from patients with VBT TBE responded with lower levels of IFN-α and the proinflammatory cytokines IL-12 (p70) and IL-15 after 24- and 48-hour in vitro stimulation with TBEV, possibly facilitating viral replication and influencing the development of cell-mediated immunity. On the other hand, significantly higher levels of IL-6 in addition to an observed trend of higher expression of TNF-α measured after 6 days of in vitro stimulation of PBMC could support disruption of the blood-brain barrier and promote viral and immune cell influx into the CNS, leading to more severe disease in VBT TBE patients., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Marušić, Kopitar, Korva, Knap, Bogovič, Strle, Ihan and Avšič-Županc.) more...
- Published
- 2023
- Full Text
- View/download PDF
39. Intrahost Monkeypox Virus Genome Variation in Patient with Early Infection, Finland, 2022.
- Author
-
Vauhkonen H, Kallio-Kokko H, Hiltunen-Back E, Lönnqvist L, Leppäaho-Lakka J, Mannonen L, Kant R, Sironen T, Kurkela S, Lappalainen M, Zorec TM, Zakotnik S, Vlaj D, Korva M, Avšič-Županc T, Poljak M, Smura T, and Vapalahti O more...
- Subjects
- Humans, Finland, Mutation, Monkeypox virus, Mpox, Monkeypox
- Abstract
Monkeypox virus was imported into Finland during late May-early June 2022. Intrahost viral genome variation in a sample from 1 patient comprised a major variant with 3 lineage B.1.3-specific mutations and a minor variant with ancestral B.1 nucleotides. Results suggest either ongoing APOBEC3 enzyme-mediated evolution or co-infection. more...
- Published
- 2023
- Full Text
- View/download PDF
40. Comparison of laboratory and immune characteristics of the initial and second phase of tick-borne encephalitis.
- Author
-
Bogovič P, Kastrin A, Lotrič-Furlan S, Ogrinc K, Avšič Županc T, Korva M, Knap N, Resman Rus K, Strle K, and Strle F
- Subjects
- Adult, B-Lymphocytes, Humans, Encephalitis Viruses, Tick-Borne, Encephalitis, Tick-Borne, Meningoencephalitis
- Abstract
Tick-borne encephalitis (TBE) usually has a biphasic course which begins with unspecific febrile illness, followed by central nervous system involvement. Because TBE is not yet suspected during the initial phase, knowledge of early TBE pathogenesis is incomplete. Herein we evaluated laboratory and immune findings in the initial and second (meningoencephalitic) phase of TBE in 88 well-defined adult patients. Comparison of nine laboratory blood parameters in both phases of TBE revealed that laboratory abnormalities, consisting of low leukocyte and platelet counts and increased liver enzymes levels, were predominately associated with the initial phase of TBE and resolved thereafter. Assessment of 29 immune mediators in serum during the initial phase, and in serum and cerebrospinal fluid (CSF) during the second phase of TBE revealed highly distinct clustering patterns among the three groups. In the initial phase of TBE, the primary finding in serum was a rather heterogeneous immune response involving innate (CXCL11), B cell (CXCL13, BAFF), and T cell mediators (IL-27 and IL-4). During the second phase of TBE, growth factors associated with angiogenesis (GRO-α and VEGF-A) were the predominant characteristic in serum, whereas innate and Th1 mediators were the defining feature of immune responses in CSF. These findings imply that distinct immune processes play a role in the pathophysiology of different phases of TBE and in different compartments. more...
- Published
- 2022
- Full Text
- View/download PDF
41. In human astrocytes neurotropic flaviviruses increase autophagy, yet their replication is autophagy-independent.
- Author
-
Tavčar Verdev P, Potokar M, Korva M, Resman Rus K, Kolenc M, Avšič Županc T, Zorec R, and Jorgačevski J
- Subjects
- Animals, Humans, Wortmannin metabolism, Autophagy, Sirolimus, Virus Replication, Astrocytes metabolism, Encephalitis Viruses, Tick-Borne
- Abstract
Astrocytes, an abundant type of glial cells, are the key cells providing homeostasis in the central nervous system. Due to their susceptibility to infection, combined with high resilience to virus-induced cell death, astrocytes are now considered one of the principal types of cells, responsible for virus retention and dissemination within the brain. Autophagy plays an important role in elimination of intracellular components and in maintaining cellular homeostasis and is also intertwined with the life cycle of viruses. The physiological significance of autophagy in astrocytes, in connection with the life cycle and transmission of viruses, remains poorly investigated. In the present study, we investigated flavivirus-induced modulation of autophagy in human astrocytes by monitoring a tandem fluorescent-tagged LC3 probe (mRFP-EGFP-LC3) with confocal and super-resolution fluorescence microscopy. Astrocytes were infected with tick-borne encephalitis virus (TBEV) or West Nile virus (WNV), both pathogenic flaviviruses, and with mosquito-only flavivirus (MOF), which is considered non-pathogenic. The results revealed that human astrocytes are susceptible to infection with TBEV, WNV and to a much lower extent also to MOF. Infection and replication rates of TBEV and WNV are paralleled by increased rate of autophagy, whereas autophagosome maturation and the size of autophagic compartments are not affected. Modulation of autophagy by rapamycin and wortmannin does not influence TBEV and WNV replication rate, whereas bafilomycin A1 attenuates their replication and infectivity. In human astrocytes infected with MOF, the low infectivity and the lack of efficient replication of this flavivirus are mirrored by the absence of an autophagic response., (© 2022. The Author(s).) more...
- Published
- 2022
- Full Text
- View/download PDF
42. Milder outcomes of SARS-CoV-2 genetically confirmed reinfections compared to primary infections with the delta variant: A retrospective case-control study.
- Author
-
Suljič A, Sočan M, Mrzel M, Lunar MM, Korva M, Štorman A, Prosenc K, Janežič S, Žohar-Čretnik T, Zupanič T, Poljak M, and Avšič-Županc T
- Abstract
Background: SARS-CoV-2 infection does not confer long immunity. However, studies suggest that prior infection is associated with lower risk of reinfection and milder outcomes of recurrent infections. The aims of this retrospective observational case-control study were to describe the clinical and molecular characteristics of genetically confirmed Delta reinfection cases and to assess the potential protective role of preceding infection on the severity of reinfection., Methods: We used next generation sequencing (NGS) to explore if cases with two positive real time RT-PCR tests > 90 days apart were infected with a different SARS-CoV-2 variant. Cases with confirmed reinfection between August 1st and October 31st, 2021 (the Delta wave) in Slovenia were matched 1:4 by age, sex and timeframe (week of positive test) with individuals with primary infection. Sociodemographic and epidemiologic data, vaccination status, and data on hospitalization and outcome of infection were retrieved from several centralized and standardized national databases. Additional epidemiologic surveys were performed on a limited number of cases and controls., Results: We identified 628 cases of genetically confirmed reinfection during the study period and matched them with 2,512 control subjects with Delta primary infection. Primary infections in individuals with reinfection were mainly caused by B.1.258.17 (51.1%), followed by B.1.1.7 (15.1%) and reinfection was detected on average 271 days after primary infection (range 101-477 days). Our results show a substantially lower probability of hospitalization in cases with reinfection compared with controls (OR: 0.21, p = 0.017), but no significant difference was observed in intensive care unit admission and deaths. We observed a significantly lower proportion of vaccinated individuals among cases compared to controls (4.5% vs. 28.2%), suggesting that hybrid immunity leads to lower probability of reinfection. Detailed analysis of the temporal distribution of variants, responsible for reinfections, showed no significant differences in reinfection potential., Conclusion: Reinfection with the SARS-CoV-2 Delta variant resulted in fewer hospitalizations compared to the primary Delta infection, suggesting that primary infection may, to some extent, produce at least short lasting protective immunity. This study provides additional insight into the reinfection dynamics that may allow appropriate public health measures to be taken in subsequent waves of the COVID-19 pandemic., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Suljič, Sočan, Mrzel, Lunar, Korva, Štorman, Prosenc, Janežič, Žohar-Čretnik, Zupanič, Poljak and Avšič-Županc.) more...
- Published
- 2022
- Full Text
- View/download PDF
43. Vector-Borne Tularemia: A Re-Emerging Cause of Cervical Lymphadenopathy.
- Author
-
Troha K, Božanić Urbančič N, Korva M, Avšič-Županc T, Battelino S, and Vozel D
- Abstract
Tularemia is a zoonosis caused by the highly invasive bacterium Francisella tularensis . It is transmitted to humans by direct contact with infected animals or by vectors, such as ticks, mosquitos, and flies. Even though it is well-known as a tick-borne disease, it is usually not immediately recognised after a tick bite. In Slovenia, tularemia is rare, with 1-3 cases reported annually; however, the incidence seems to be increasing. Ulceroglandular tularemia is one of its most common forms, with cervical colliquative lymphadenopathy as a frequent manifestation. The diagnosis of tularemia largely relies on epidemiological information, clinical examination, imaging, and molecular studies. Physicians should consider this disease a differential diagnosis for a neck mass, especially after a tick bite, as its management significantly differs from that of other causes. Tularemia-associated lymphadenitis is treated with antibiotics and surgical drainage of the colliquated lymph nodes. Additionally, tularemia should be noted for its potential use in bioterrorism on behalf of the causative agents' low infectious dose, possible aerosol formation, no effective vaccine at disposal, and the ability to produce severe disease. This article reviews the recent literature on tularemia and presents a case of an adult male with tick-borne cervical ulceroglandular tularemia. more...
- Published
- 2022
- Full Text
- View/download PDF
44. Evaluation of Two Broadly Used Commercial Methods for Detection of Respiratory Viruses with a Recently Added New Target for Detection of SARS-CoV-2.
- Author
-
Jevšnik Virant M, Uršič T, Kogoj R, Korva M, Petrovec M, and Avšič-Županc T
- Subjects
- COVID-19 Testing, Humans, SARS-CoV-2 genetics, Sensitivity and Specificity, COVID-19 diagnosis, Viruses
- Abstract
The clinical symptoms caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are nonspecific and can be associated with most other respiratory viruses that cause acute respiratory tract infections (ARI). Because the clinical differentiation of COVID-19 patients from those with other respiratory viruses is difficult, the evaluation of automated methods to detect important respiratory viruses together with SARS-CoV-2 seems necessary. Therefore, this study compares two molecular assays for the detection of respiratory viruses, including SARS-CoV-2: the Respiratory Viruses 16-Well Assay (AusDiagnostics, Pty Ltd., Mascot, Australia) and the Allplex™ RV Essential Assay coupled with the Allplex™-nCoV Assay (Seegene Inc., Seoul, Korea). The two methods (AusDiagnostics and Alplex
TM -nCoV Assay SARS-CoV-2) had 98.6% agreement with the reference method, cobas 6800, for the detection of SARS-CoV-2. Agreement between the AusDiagnostics assay and the AlplexTM RV Essential Assay for the detection of seven respiratory viruses was 99%. In our experience, the Respiratory Viruses 16-Well Assay proved to be the most valuable and useful medium-throughput method for simultaneous detection of important respiratory viruses and SARS-CoV-2. The main advantages of the method are high specificity for all targets included and their simultaneous detection and medium throughput with the option of having multiple instruments provide a constant run. more...- Published
- 2022
- Full Text
- View/download PDF
45. Complete Genome Sequencing of Tick-Borne Encephalitis Virus Directly from Clinical Samples: Comparison of Shotgun Metagenomic and Targeted Amplicon-Based Sequencing.
- Author
-
Zakotnik S, Knap N, Bogovič P, Zorec TM, Poljak M, Strle F, Avšič-Županc T, and Korva M
- Subjects
- Base Sequence, Genes, Viral, Humans, Whole Genome Sequencing, Encephalitis Viruses, Tick-Borne genetics, Encephalitis, Tick-Borne diagnosis
- Abstract
The clinical presentation of tick-borne encephalitis virus (TBEV) infection varies from asymptomatic to severe meningoencephalitis or meningoencephalomyelitis. The TBEV subtype has been suggested as one of the most important risk factors for disease severity, but TBEV genetic characterization is difficult. Infection is usually diagnosed in the post-viremic phase, and so relevant clinical samples of TBEV are extremely rare and, when present, are associated with low viral loads. To date, only two complete TBEV genomes sequenced directly from patient clinical samples are publicly available. The aim of this study was to develop novel protocols for the direct sequencing of the TBEV genome, enabling studies of viral genetic determinants that influence disease severity. We developed a novel oligonucleotide primer scheme for amplification of the complete TBEV genome. The primer set was tested on 21 clinical samples with various viral loads and collected over a 15-year period using the two most common sequencing platforms. The amplicon-based strategy was compared to direct shotgun sequencing. Using the novel primer set, we successfully obtained nearly complete TBEV genomes (>90% of genome) from all clinical samples, including those with extremely low viral loads. Comparison of consensus sequences of the TBEV genome generated using the novel amplicon-based strategy and shotgun sequencing showed no difference. We conclude that the novel primer set is a powerful tool for future studies on genetic determinants of TBEV that influence disease severity and will lead to a better understanding of TBE pathogenesis. more...
- Published
- 2022
- Full Text
- View/download PDF
46. Comparative Evaluation of Six SARS-CoV-2 Real-Time RT-PCR Diagnostic Approaches Shows Substantial Genomic Variant-Dependent Intra- and Inter-Test Variability, Poor Interchangeability of Cycle Threshold and Complementary Turn-Around Times.
- Author
-
Kogoj R, Korva M, Knap N, Resman Rus K, Pozvek P, Avšič-Županc T, and Poljak M
- Abstract
Several professional societies advise against using real-time Reverse-Transcription PCR (rtRT-PCR) cycle threshold (Ct) values to guide clinical decisions. We comparatively assessed the variability of Ct values generated by six diagnostic approaches by testing serial dilutions of well-characterized isolates of 10 clinically most relevant SARS-CoV-2 genomic variants: Alpha, Beta, Gamma, Delta, Eta, Iota, Omicron, A.27, B.1.258.17, and B.1 with D614G mutation. Comparison of three fully automated rtRT-PCR analyzers and a reference manual rtRT-PCR assay using RNA isolated with three different nucleic acid isolation instruments showed substantial inter-variant intra-test and intra-variant inter-test variability. Ct value differences were dependent on both the rtRT-PCR platform and SARS-CoV-2 genomic variant. Differences ranging from 2.0 to 8.4 Ct values were observed when testing equal concentrations of different SARS-CoV-2 variants. Results confirm that Ct values are an unreliable surrogate for viral load and should not be used as a proxy of infectivity and transmissibility, especially when different rtRT-PCR assays are used in parallel and multiple SARS-CoV-2 variants are circulating. A detailed turn-around time (TAT) comparative assessment showed substantially different TATs, but parallel use of different diagnostic approaches was beneficial and complementary, allowing release of results for more than 81% of non-priority samples within 8 h after admission. more...
- Published
- 2022
- Full Text
- View/download PDF
47. Unique Clinical, Immune, and Genetic Signature in Patients with Borrelial Meningoradiculoneuritis 1 .
- Author
-
Ogrinc K, Hernández SA, Korva M, Bogovič P, Rojko T, Lusa L, Chiumento G, Strle F, and Strle K
- Subjects
- Chemokines metabolism, Europe, Humans, Prevalence, Borrelia, Cytokines metabolism, Facial Paralysis, Lyme Neuroborreliosis cerebrospinal fluid, Lyme Neuroborreliosis diagnosis, Lyme Neuroborreliosis genetics
- Abstract
Lyme neuroborreliosis (LNB) in Europe may manifest with painful meningoradiculoneuritis (also known as Bannwarth syndrome) or lymphocytic meningitis with or without cranial neuritis (peripheral facial palsy). We assessed host immune responses and the prevalence of TLR1 (toll-like receptor 1)-1805GG polymorphism to gain insights into the pathophysiology of these conditions. Regardless of LNB manifestation, most mediators associated with innate and adaptive immune responses were concentrated in cerebrospinal fluid; serum levels were unremarkable. When stratified by specific clinical manifestation, patients with meningoradiculoneuritis had higher levels of B-cell chemoattractants CXC motif chemokine ligand (CXCL) 12 and CXCL13 and T-cell-associated mediators CXCL9, CXCL10, and interleukin 17, compared with those without radicular pain. Moreover, these patients had a higher frequency of TLR1-1805GG polymorphism and more constitutional symptoms. These findings demonstrate that meningoradiculoneuritis is a distinct clinical entity with unique immune and genetic pathophysiology, providing new considerations for the study of LNB and borrelial meningoradiculitis. more...
- Published
- 2022
- Full Text
- View/download PDF
48. Exposure to dust, endotoxins and microbes in Finnish vegetable greenhouses.
- Author
-
Suuronen K, Hölttä P, Korva M, and Koponen M
- Subjects
- Dust analysis, Endotoxins analysis, Environmental Monitoring methods, Finland, Humans, Inhalation Exposure analysis, Language, Vegetables, Air Pollutants, Occupational analysis, Occupational Exposure analysis
- Abstract
Introduction and Objective: In Finland and other northern countries, vegetable greenhouse workers are exposed to airborne dust and microbes all year round. The aim of the study was to assess respiratory exposure to dust, endotoxins and microbes, and to identify the risk phases of respiratory and skin exposure to promote safe working methods., Material and Methods: Work in greenhouses was observed and recorded in a structured form. 23 personal samples and eight stationary samples of dust, endotoxins and viable microbes were collected from eight tomato or cucumber greenhouses in Finland. Dust samples were analysed gravimetrically. Endotoxins were analysed on filters by chromogenic Limulus amoebocyte lysate assay. Microbes were collected on filters, incubated and counted in three different culture media. Eight additional stationary samples of microbes were collected on a six-phase impactor., Results: The greenhouses were generally clean and well organised, but skin protection was deficient. The median of personal dust exposure was 0.24 mg/m
3 : 0.21 mg/m3 in the tomatohouses and 0.62 mg/m3 in the cucumber greenhouses. The mean level of bacteria in the tomato houses was 2.7 × 103 and in the cucumber houses 1.6×104 . Those of fungi were 3.6 × 105 and 1.7 × 105 on Hagem and 8.1 × 105 and 1.9 × 105 on DG-18, respectively. The microbes made up about 1/10 of these values in the stationary samples. Very low concentrations of endotoxins were found in 5/23 air samples., Conclusions: The clean appearance of the greenhouses was reflected in the low to moderate levels of dust. Risk phases of high exposure, such as lifting leaf debris, were identified. The microbe species were typical of this climate, and their levels were comparable to other greenhouse studies, but lower than in farming. Prevention among the foreign workforce is challenging due to the lack of a common language. more...- Published
- 2022
- Full Text
- View/download PDF
49. Clinical and Laboratory Characteristics and Outcome of Illness Caused by Tick-Borne Encephalitis Virus without Central Nervous System Involvement.
- Author
-
Bogovič P, Kastrin A, Lotrič-Furlan S, Ogrinc K, Županc TA, Korva M, Knap N, and Strle F
- Subjects
- Antibodies, Viral, Central Nervous System, Humans, RNA, Viral genetics, Viral Load, Encephalitis Viruses, Tick-Borne genetics, Encephalitis, Tick-Borne diagnosis, Encephalitis, Tick-Borne epidemiology
- Abstract
Information on febrile illness caused by tick-borne encephalitis virus (TBEV) without central nervous system involvement is limited. We characterized 98 patients who had TBEV RNA in their blood but no central nervous system involvement at the time of evaluation. Median duration of illness was 7 days; 37 (38%) patients were hospitalized. The most frequent findings were malaise or fatigue (98%), fever (97%), headache (86%), and myalgias (54%); common laboratory findings were leukopenia (88%), thrombocytopenia (59%), and abnormal liver test results (63%). During the illness, blood leukocyte counts tended to improve, whereas thrombocytopenia and liver enzymes tended to deteriorate. At the time of positive PCR findings, 0/98 patients had serum IgG TBEV and 7 serum IgM TBEV; all patients later seroconverted. Viral RNA load was higher in patients with more severe illness but did not differ substantially in relation to several other factors. Illness progressed to tick-borne encephalitis in 84% of patients within 18 days after defervescence. more...
- Published
- 2022
- Full Text
- View/download PDF
50. Transmission of SARS-CoV-2 from Human to Domestic Ferret.
- Author
-
Račnik J, Kočevar A, Slavec B, Korva M, Rus KR, Zakotnik S, Zorec TM, Poljak M, Matko M, Rojs OZ, and Županc TA
- Subjects
- Animals, Humans, SARS-CoV-2, Slovenia, COVID-19, Ferrets
- Abstract
We report a case of natural infection with severe acute respiratory syndrome coronavirus 2 transmitted from an owner to a pet ferret in the same household in Slovenia. The ferret had onset of gastroenteritis with severe dehydration. Whole-genome sequencing of the viruses isolated from the owner and ferret revealed a 2-nt difference. more...
- Published
- 2021
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.